Vanguard

Annual Report | December 31, 2023

Vanguard Variable Insurance Funds

Total Stock Market Index Portfolio (with underlying Equity Index Portfolio)

See the inside front cover for important information about your fund's annual and semiannual shareholder reports.

Important information about shareholder reports

Beginning in July 2024, amendments adopted by the Securities and Exchange Commission will substantially impact the design, content, and transmission of shareholder reports. Shareholder reports will provide key fund information in a clear and concise format and must be mailed to each shareholder that has not elected to receive the reports electronically. Financial statements will no longer be included in the shareholder report but will be available at vanguard.com, can be mailed upon request, or can be accessed on the SEC's website at www.sec.gov.

You may elect to receive shareholder reports and other communications from the fund electronically by contacting your financial intermediary (such as a broker-dealer or bank) or, if you invest directly with the fund, by calling Vanguard at one of the phone numbers on the back cover of this report or by logging on to vanguard.com.

Contents

Your Portfolio's Performance at a Glance1
About Your Portfolio's Expenses2
Performance Summary
Financial Statements5

Your Portfolio's Performance at a Glance

• For the 12 months ended December 31, 2023, the Total Stock Market Index Portfolio returned 25.95%, in line with the 26.06% return of its composite index after factoring in the portfolio's expenses.

• The portfolio, which invests in Vanguard Variable Insurance Funds Equity Index Portfolio and Vanguard Extended Market Index Fund, provides exposure to every segment, size, and style of the U.S. equity market.

• The fourth quarter of 2023 was a volatile period for the financial markets. Stocks and bonds continued to lose ground early on amid concerns that interest rates might remain elevated for an extended period. They went on to post strong gains, however, as inflation remained on a downward trend and economic growth softened, leading the markets to anticipate that policy rates had reached their peak and that cuts were likely not too far down the road.

• For the decade ended December 31, the portfolio's average annual return was 11.29%, in line with its benchmark average of 11.40%.

Market Barometer

	Average Annual Total Returns Periods Ended December 31, 2023		
	One Year	Three Years	Five Years
Stocks			
Russell 1000 Index (Large-caps)	26.53%	8.97%	15.52%
Russell 2000 Index (Small-caps)	16.93	2.22	9.97
Russell 3000 Index (Broad U.S. market)	25.96	8.54	15.16
FTSE All-World ex US Index (International)	15.82	1.98	7.52
Bonds			
Bloomberg U.S. Aggregate Float Adjusted Index (Broad taxable market)	5.60%	-3.33%	1.17%
Bloomberg Municipal Bond Index (Broad tax-exempt market)	6.40	-0.40	2.25
FTSE Three-Month U.S. Treasury Bill Index	5.26	2.24	1.91
CPI			
Consumer Price Index	3.35%	5.60%	4.07%

About Your Portfolio's Expenses

As a shareholder of the portfolio, you incur ongoing costs, which include costs for portfolio management, administrative services, and shareholder reports (like this one), among others. Operating expenses, which are deducted from a portfolio's gross income, directly reduce the investment return of the portfolio.

A portfolio's expenses are expressed as a percentage of its average net assets. The Total Stock Market Index Portfolio has no direct expenses, but bears its proportionate share of the costs for the underlying funds in which it invests. These indirect expenses make up the acquired fund fees and expenses, also expressed as a percentage of average net assets. The following examples are intended to help you understand the ongoing costs (in dollars) of investing in your portfolio and to compare these costs with those of other mutual funds. The examples are based on an investment of \$1,000 made at the beginning of the period shown and held for the entire period. The costs were calculated using the acquired fund fees and expenses for the Total Stock Market Index Portfolio.

The accompanying table illustrates your portfolio's costs in two ways:

• Based on actual portfolio return. This section helps you to estimate the actual expenses that you paid over the period. The "Ending Account Value" shown is derived from the portfolio's actual return, and the third column shows the dollar amount that would have been paid by an investor who started with \$1,000 in the portfolio. You may use the information here, together with the amount you invested, to estimate the expenses that you paid over the period.

To do so, simply divide your account value by \$1,000 (for example, an \$8,600 account value divided by \$1,000 = 8.6), then multiply the result by the number given for your portfolio under the heading "Expenses Paid During Period."

• Based on hypothetical 5% yearly return. This section is intended to help you compare your portfolio's costs with those of other mutual funds. It assumes that the portfolio had a yearly return of 5% before expenses, but that the expense ratio is unchanged. In this case—because the return used is not the portfolio's actual return—the results do not apply to your investment. The example is useful in making comparisons because the Securities and Exchange Commission requires all mutual funds to calculate expenses based on a 5% return. You can assess your portfolio's costs by comparing this hypothetical example with the hypothetical examples that appear in shareholder reports of other funds.

Note that the expenses shown in the table are meant to highlight and help you compare *ongoing* costs only. The portfolio's expense ratio does not reflect additional fees and expenses associated with the annuity or life insurance program through which you invest.

The calculations assume no shares were bought or sold during the period. Your actual costs may have been higher or lower, depending on the amount of your investment and the timing of any purchases or redemptions.

You can find more information about the portfolio's expenses in the Financial Statements section of this report. For additional information on operating expenses and other shareholder costs, please refer to your portfolio's current prospectus.

Six Months Ended December 31, 2023

	Beginning Account Value	Ending Account Value	Expenses Paid During
Total Stock Market Index Portfolio	6/30/2023	12/31/2023	Period
Based on Actual Portfolio Return	\$1,000.00	\$1,084.20	\$0.68
Based on Hypothetical 5% Yearly Return	1,000.00	1,024.55	0.66


The calculations are based on acquired fund fees and expenses for the most recent six-month period. The underlying portfolios' annualized expense figure for that period is 0.13%. The dollar amounts shown as "Expenses Paid" are equal to the annualized average weighted expense ratio for the underlying funds multiplied by the average account value over the period, multiplied by the number of days in the most recent six-month period, then divided by the number of days in the most recent 12-month period (184/365).

Total Stock Market Index Portfolio

Performance Summary

All of the returns in this report represent past performance, which is not a guarantee of future results that may be achieved by the portfolio. (Current performance may be lower or higher than the performance data cited. For performance data current to the most recent month-end, visit our website at vanguard.com/performance.) Note, too, that both investment returns and principal value can fluctuate widely, so an investor's shares, when sold, could be worth more or less than their original cost. The returns shown do not reflect taxes that a shareholder would pay on portfolio distributions or on the sale of portfolio shares. Nor do the returns reflect fees and expenses associated with the annuity or life insurance program through which a shareholder invests. If these fees and expenses were included, the portfolio's returns would be lower.

Cumulative Performance: December 31, 2013, Through December 31, 2023 Initial Investment of \$10,000



	Average Annual Total Returns Periods Ended December 31, 2023			
	One Year	Five Years	Ten Years	Final Value of a \$10,000 Investment
Total Stock Market Index Portfolio	25.95%	14.93%	11.29%	\$29,135
	26.06	15.05	11.40	29,437

Underlying Vanguard Funds As of December 31, 2023

Vanguard Variable Insurance Funds—Equity Index Portfolio	85.8%
Vanguard Extended Market Index Fund Admiral Shares	14.2

The table reflects the portfolio's investments, except for short-term investments.

Financial Statements

Schedule of Investments

As of December 31, 2023

The portfolio files its complete schedule of portfolio holdings with the Securities and Exchange Commission (SEC) for the first and third quarters of each fiscal year as an exhibit to its reports on Form N-PORT. The portfolio's Form N-PORT reports are available on the SEC's website at www.sec.gov.

	Shares	Market Value• (\$000)
Investment Companies (100.1%)		
U.S. Stock Funds (100.1%) Vanguard Variable Insurance Funds—Equity Index Portfolio Vanguard Extended Market Index Fund Admiral Shares	61,410,232 4,971,396	
Total Investment Companies (Cost \$3,230,887)		4,359,102
Temporary Cash Investments (0.0%)		
Money Market Fund (0.0%) ¹ Vanguard Market Liquidity Fund, 5.435% (Cost \$1,708)	17,087	1,708
Total Investments (100.1%) (Cost \$3,232,595)		4,360,810
Other Assets and Liabilities—Net (-0.1%)		(4,036)
Net Assets (100%)		4,356,774

Cost is in \$000.

• See Note A in Notes to Financial Statements.

1 Affiliated money market fund available only to Vanguard funds and certain trusts and accounts managed by Vanguard. Rate shown is the 7-day yield.

Statement of Assets and Liabilities As of December 31, 2023

(\$000s, except shares, footnotes, and per-share amounts)	Amount
Assets	
Investments in Securities, at Value—Affiliated Funds (Cost \$3,232,595)	4,360,810
Receivables for Accrued Income	5
Receivables for Capital Shares Issued	969
Total Assets	4,361,784
Liabilities	
Payables for Investment Securities Purchased	1,710
Payables for Capital Shares Redeemed	3,300
Total Liabilities	5,010
Net Assets	4,356,774

At December 31, 2023, net assets consisted of:

Net Asset Value Per Share	\$49.45
Applicable to 88,095,766 outstanding \$.001 par value shares of beneficial interest (unlimited authorization)	4,356,774
Net Assets	
Net Assets	4,356,774
Total Distributable Earnings (Loss)	1,521,677
Paid-in Capital	2,835,097

Statement of Operations

	Year Ended December 31, 2023
	(\$000)
Investment Income	
Income	
Income Distributions Received from Affiliated Funds	58,154
Net Investment Income-Note B	58,154
Realized Net Gain (Loss)	
Capital Gain Distributions Received from Affiliated Funds	110,292
Affiliated Funds Sold	227,201
Futures Contracts	6
Realized Net Gain (Loss)	337,499
Change in Unrealized Appreciation (Depreciation) from Affiliated Funds	545,038
Net Increase (Decrease) in Net Assets Resulting from Operations	940,691

Statement of Changes in Net Assets

	Year Ended December 31,	
	2023 (\$000)	2022 (\$000)
Increase (Decrease) in Net Assets		
Operations		
Net Investment Income	58,154	47,569
Realized Net Gain (Loss)	337,499	231,640
Change in Unrealized Appreciation (Depreciation)	545,038	(1,120,049)
Net Increase (Decrease) in Net Assets Resulting from Operations	940,691	(840,840)
Distributions		
Total Distributions	(279,097)	(311,453)
Capital Share Transactions		
Issued	530,697	653,617
Issued in Lieu of Cash Distributions	279,097	311,453
Redeemed	(728,124)	(453,339)
Net Increase (Decrease) from Capital Share Transactions	81,670	511,731
Total Increase (Decrease)	743,264	(640,562)
Net Assets		
Beginning of Period	3,613,510	4,254,072
End of Period	4,356,774	3,613,510

Financial Highlights

For a Share Outstanding			Year	- Ended Dec	ember 31,
Throughout Each Period	2023	2022	2021	2020	2019
Net Asset Value, Beginning of Period	\$42.30	\$56.94	\$48.56	\$42.81	\$34.26
Investment Operations					
Net Investment Income ¹	.647	.587	.640	.678	.694
Capital Gain Distributions Received ¹	1.227	1.704	1.599	.684	.789
Net Realized and Unrealized Gain (Loss) on Investments	8.422	(12.797)	9.589	6.354	8.792
Total from Investment Operations	10.296	(10.506)	11.828	7.716	10.275
Distributions					
Dividends from Net Investment Income	(.536)	(.650)	(.652)	(.671)	(.618)
Distributions from Realized Capital Gains	(2.610)	(3.484)	(2.796)	(1.295)	(1.107)
Total Distributions	(3.146)	(4.134)	(3.448)	(1.966)	(1.725)
Net Asset Value, End of Period	\$49.45	\$42.30	\$56.94	\$48.56	\$42.81
Total Return	25.95%	-19.59%	25.64%	20.55%	30.75%
Ratios/Supplemental Data					
Net Assets, End of Period (Millions)	\$4,357	\$3,614	\$4,254	\$3,462	\$2,757
Ratio of Total Expenses to Average Net Assets	_	_	_	_	_
Acquired Fund Fees and Expenses	0.13%	0.13%	0.13%	0.13%	0.13%
Ratio of Net Investment Income to Average Net Assets	1.45%	1.28%	1.22%	1.66%	1.79%
Portfolio Turnover Rate	12%	6%	7%	13%	4%

1 Calculated based on average shares outstanding.

Notes to Financial Statements

The Total Stock Market Index Portfolio, a portfolio of Vanguard Variable Insurance Funds, is registered under the Investment Company Act of 1940 as an open-end investment company. The portfolio seeks to match the return of its target index by investing in selected Vanguard funds and portfolios. The portfolio invests a substantial amount of its assets in VVIF Equity Index Portfolio. The accompanying financial statements of VVIF Equity Index Portfolio should be read in conjunction with the financial statements of the portfolio. Financial statements and other information about each underlying fund and portfolio are available at www.vanguard.com. The portfolio's shares are only available for purchase by separate accounts of insurance companies as investments for variable annuity plans, variable life insurance contracts, or other variable benefit insurance contracts.

A. The following significant accounting policies conform to generally accepted accounting principles for U.S. investment companies. The portfolio consistently follows such policies in preparing its financial statements.

1. Security Valuation: Investments are valued at the net asset value of each underlying Vanguard fund determined as of the close of the New York Stock Exchange (generally 4 p.m., Eastern time) on the valuation date.

2. Futures Contracts: The portfolio uses stock and bond futures contracts to a limited extent, with the objectives of maintaining full exposure to the market and maintaining its target asset allocation. The primary risks associated with the use of futures contracts are imperfect correlation between changes in market values of investments held by the portfolio and the prices of futures contracts, and the possibility of an illiquid market. Counterparty risk involving futures is mitigated because a regulated clearinghouse is the counterparty instead of the clearing broker. To further mitigate counterparty risk, the portfolio trades futures contracts on an exchange, monitors the financial strength of its clearing brokers and clearinghouse, and has entered into clearing agreements with its clearing brokers. The clearinghouse imposes initial margin requirements to secure the portfolio's performance and requires daily settlement of variation margin representing changes in the market value of each contract. Any securities pledged as initial margin for open contracts are noted in the Schedule of Investments.

Futures contracts are valued at their quoted daily settlement prices. The notional amounts of the contracts are not recorded in the Statement of Assets and Liabilities. Fluctuations in the value of the contracts are recorded in the Statement of Assets and Liabilities as an asset (liability) and in the Statement of Operations as unrealized appreciation (depreciation) until the contracts are closed, when they are recorded as realized gains (losses) on futures contracts.

During the year ended December 31, 2023, the portfolio's average investments in long and short futures contracts represented less than 1% and 0% of net assets, respectively, based on the average of the notional amounts at each quarter-end during the period. The portfolio had no open futures contracts at December 31, 2023.

3. Federal Income Taxes: The portfolio intends to continue to qualify as a regulated investment company and distribute virtually all of its taxable income. The portfolio's tax returns are open to examination by the relevant tax authorities until expiration of the applicable statute of limitations, which is generally three years after the filing of the tax return. Management has analyzed the portfolio's tax positions taken for all open federal and state income tax years, and has concluded that no provision for income tax is required in the portfolio's financial statements.

4. Distributions: Distributions to shareholders are recorded on the ex-dividend date. Distributions are determined on a tax basis at the fiscal year-end and may differ from net investment income and realized capital gains for financial reporting purposes.

5. Credit Facilities and Interfund Lending Program: The portfolio and certain other funds managed by The Vanguard Group ("Vanguard") participate in a \$4.3 billion committed credit facility provided by a syndicate of lenders pursuant to a credit agreement and an uncommitted credit facility provided by Vanguard. Both facilities may be renewed annually. Each fund is individually liable for its borrowings, if any, under the credit facilities. Borrowings may be utilized for temporary or emergency purposes and are subject to the portfolio's regulatory and contractual borrowing restrictions. With respect to the committed credit facility, the participating funds are charged administrative fees and an annual commitment fee of 0.10% of the undrawn committed amount of the facility, which are allocated to the funds based on a method approved by the portfolio's board of trustees and borne by the funds in which the portfolio invests (see Note B). Any borrowings under either facility bear interest at an agreed-upon spread plus the higher of the federal funds effective rate, the overnight bank funding rate, or the Daily Simple Secured Overnight Financing Rate inclusive of an additional agreed-upon spread. However, borrowings under the uncommitted credit facility may bear interest based upon an alternate rate agreed to by the portfolio and Vanguard.

In accordance with an exemptive order (the "Order") from the SEC, the portfolio may participate in a joint lending and borrowing program that allows registered open-end Vanguard funds to borrow money from and lend money to each other for temporary or emergency purposes (the "Interfund Lending Program"), subject to compliance with the terms and conditions of the Order, and to the extent permitted by the portfolio's investment objective and investment policies. Interfund loans and borrowings normally extend overnight but can have a maximum duration of seven days. Loans may be called on one business day's notice. The interest rate to be charged is governed by the conditions of the Order and internal procedures adopted by the board of trustees. The board of trustees is responsible for overseeing the Interfund Lending Program.

For the year ended December 31, 2023, the portfolio did not utilize the credit facilities or the Interfund Lending Program.

6. Other: Income and capital gain distributions received are recorded on the ex-dividend date. Security transactions are accounted for on the date securities are bought or sold. Costs used to determine realized gains (losses) on the sale of investment securities are those of the specific securities sold.

B. In accordance with the terms of a Funds' Service Agreement (the "FSA") between Vanguard and the portfolio, Vanguard furnishes to the portfolio investment advisory, corporate management, administrative, marketing, and distribution services at Vanguard's cost of operations (as defined by the FSA). These costs of operations are allocated to the portfolio based on methods and guidelines approved by the board of trustees. The FSA provides that expenses otherwise allocable to Vanguard funds-of-funds may be reduced or eliminated to the extent of savings realized by the underlying Vanguard funds by virtue of being part of a fund-of-funds. Accordingly, all expenses for services provided by Vanguard to the portfolio and all other expenses incurred by the portfolio during the year ended December 31, 2023, were borne by the underlying Vanguard funds in which the portfolio invests. The portfolio's trustees and officers are also trustees and officers, respectively, of the underlying Vanguard funds, as well as directors and employees, respectively, of Vanguard.

C. Various inputs may be used to determine the value of the portfolio's investments. These inputs are summarized in three broad levels for financial statement purposes. The inputs or methodologies used to value securities are not necessarily an indication of the risk associated with investing in those securities.

Level 1—Quoted prices in active markets for identical securities.

Level 2—Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).

Level 3—Significant unobservable inputs (including the portfolio's own assumptions used to determine the fair value of investments). Any investments valued with significant unobservable inputs are noted on the Schedule of Investments.

At December 31, 2023, 100% of the market value of the portfolio's investments was determined based on Level 1 inputs.

D. Permanent differences between book-basis and tax-basis components of net assets, if any, are reclassified among capital accounts in the financial statements to reflect their tax character. These reclassifications have no effect on net assets or net asset value per share.

Temporary differences between book-basis and tax-basis components of total distributable earnings (loss) arise when certain items of income, gain, or loss are recognized in different periods for financial statement and tax purposes; these differences will reverse at some time in the future. The differences are primarily related to the deferral of losses from wash sales. As of period end, the tax-basis components of total distributable earnings (loss) are detailed in the table as follows:

	Amount (\$000)
Undistributed Ordinary Income	55,967
Undistributed Long-Term Gains	337,495
Net Unrealized Gains (Losses)	1,128,215
Capital Loss Carryforwards	—
Qualified Late-Year Losses	_
Other Temporary Differences	_
Total	1,521,677

The tax character of distributions paid was as follows:

·	Year Ended De	Year Ended December 31,	
	2023 Amount (\$000)	2022 Amount (\$000)	
Ordinary Income*	50,306	48,973	
Long-Term Capital Gains	228,791	262,480	
Total	279,097	311,453	

* Includes short-term capital gains, if any.

As of December 31, 2023, gross unrealized appreciation and depreciation for investments based on cost for U.S. federal income tax purposes were as follows:

	Amount (\$000)
Tax Cost	3,232,595
Gross Unrealized Appreciation	1,139,756
Gross Unrealized Depreciation	(11,541)
Net Unrealized Appreciation (Depreciation)	1,128,215

E. Capital shares issued and redeemed were:

	Year Ended December 31,	
	2023 Shares (000)	2022 Shares (000)
Issued	11,883	14,371
Issued in Lieu of Cash Distributions	6,866	6,207
Redeemed	(16,087)	(9,860)
Net Increase (Decrease) in Shares Outstanding	2,662	10,718

F. Transactions during the period in affiliated underlying Vanguard funds were as follows:

			Current Period Transactions					
	Dec. 31, 2022 Market Value (\$000)	Purchases at Cost (\$000)	Proceeds from Securities Sold (\$000)	Realized Net Gain (Loss) (\$000)	Change in Unrealized App. (Dep.) (\$000)	Income (\$000)	Capital Gain Distributions Received (\$000)	Dec. 31, 2023 Market Value (\$000)
Vanguard Extended Market Index Fund	551,411	77,629	134,745	51,702	73,837	8,331	_	619,834
Vanguard Market Liquidity Fund	344	NA ¹	NA ¹	_	_	25	_	1,708
Vanguard Variable Insurance Funds—Equity Index Portfolio	3,062,824	408,979	379,235	175,499	471,201	49,798	110,292	3,739,268
Total	3,614,579	486,608	513,980	227,201	545,038	58,154	110,292	4,360,810

1 Not applicable—purchases and sales are for temporary cash investment purposes.

G. Significant market disruptions, such as those caused by pandemics (e.g., COVID-19 pandemic), natural or environmental disasters, war (e.g., Russia's invasion of Ukraine), acts of terrorism, or other events, can adversely affect local and global markets and normal market operations. Any such disruptions could have an adverse impact on the value of the portfolio's investments and portfolio performance.

To the extent the portfolio's investment portfolio reflects concentration in a particular market, industry, sector, country or asset class, the portfolio may be adversely affected by the performance of these concentrations and may be subject to increased price volatility and other risks.

The use of derivatives may expose the portfolio to various risks. Derivatives can be highly volatile, and any initial investment is generally small relative to the notional amount so that transactions may be leveraged in terms of market exposure. A relatively small market movement may have a potentially larger impact on derivatives than on standard securities. Leveraged derivatives positions can, therefore, increase volatility. Additional information regarding the portfolio's use of derivative(s) and the specific risks associated is described under significant accounting policies.

At December 31, 2023, one shareholder (an insurance company separate account whose holdings in the portfolio represent the indirect investment of Vanguard Variable Annuity contract holders) was the record or beneficial owner of 40% of the portfolio's net assets. If this shareholder were to redeem its investment in the portfolio, the redemption might lead to the realization of taxable capital gains.

H. Management has determined that no events or transactions occurred subsequent to December 31, 2023, that would require recognition or disclosure in these financial statements.

Report of Independent Registered Public Accounting Firm

To the Board of Trustees of Vanguard Variable Insurance Funds and Shareholders of Total Stock Market Index Portfolio

Opinion on the Financial Statements

We have audited the accompanying statement of assets and liabilities, including the schedule of investments, of Total Stock Market Index Portfolio (one of the portfolios constituting Vanguard Variable Insurance Funds, referred to hereafter as the "Portfolio") as of December 31, 2023, the related statement of operations for the year ended December 31, 2023, the statement of changes in net assets for each of the two years in the period ended December 31, 2023, including the related notes, and the financial highlights for each of the five years in the period ended December 31, 2023 (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Portfolio as of December 31, 2023, the results of its operations for the year then ended, the changes in its net assets for each of the two years in the period ended December 31, 2023 and the financial highlights for each of the two years in the period ended December 31, 2023 and the financial highlights for each of the two years in the period ended December 31, 2023 and the financial highlights for each of the five years in the period ended December 31, 2023 in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Portfolio's management. Our responsibility is to express an opinion on the Portfolio's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Portfolio in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits of these financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our procedures included confirmation of securities owned as of December 31, 2023 by correspondence with the transfer agent. We believe that our audits provide a reasonable basis for our opinion.

/s/PricewaterhouseCoopers LLP Philadelphia, Pennsylvania February 15, 2024

We have served as the auditor of one or more investment companies in The Vanguard Group of Funds since 1975.

Tax information (unaudited)

For corporate shareholders, 91.1%, or if subsequently determined to be different, the maximum percentage allowable by law, of ordinary income (dividend income plus short-term gains, if any) for the fiscal year qualified for the dividends-received deduction.

The portfolio hereby designates \$286,000, or if subsequently determined to be different, the maximum amount allowable by law, of interest earned from obligations of the U.S. government which is generally exempt from state income tax.

For nonresident alien shareholders, 100% of short-term capital gain dividends distributed by the portfolio for the fiscal year are qualified short-term capital gains.

The portfolio distributed \$228,791,000 as capital gain dividends (20% rate gain distributions) to shareholders during the fiscal year.

The "S&P Total Market Index" (the "Index") is a product of S&P Dow Jones Indices LLC ("SPDJI"), and has been licensed for use by Vanguard. Standard & Poor's[®] and S&P[®] are registered trademarks of Standard & Poor's Financial Services LLC ("S&P"); Dow Jones[®] is a registered trademark of Dow Jones Trademark Holdings LLC ("Dow Jones"); S&P[®] and S&P 500[®] are trademarks of S&P; and these trademarks have been licensed for use by SPDJI and sublicensed for certain purposes by Vanguard. The Total Stock Market Index Portfolio is not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, or any of their respective affiliates (collectively, "S&P Dow Jones Indices"). S&P Dow Jones Indices makes no representation or warranty, express or implied, to the owners of the Total Stock Market Index Portfolio or any member of the public regarding the advisability of investing in securities generally or in the Total Stock Market Index portfolio particularly or the ability of the S&P Total Market Index to track general market performance. S&P Dow Jones Indices' only relationship to Vanguard with respect to the S&P Total Market Index is the licensing of the Index and certain trademarks, service marks and/or trade names of S&P Dow Jones Indices and/or its licensors. The S&P Total Market Index is determined, composed and calculated by S&P Dow Jones Indices without regard to Vanguard or the Total Stock Market Index Portfolio. S&P Dow Jones Indices has no obligation to take the needs of Vanguard or the Total Stock Market Index Portfolio or in the determination of the prices, and amount of the Total Stock Market Index Portfolio or in the determination or calculation by which the Total Stock Market Index Portfolio is to be converted into cash, surrendered or redeemed, as the case may be. S&P Dow Jones Indices has no obligation to take the needs of Vanguard or the oters in the determination of the equation by which the Total Stock Market Index Portfolio or the timing of the issuance or sale of the Total Stock Market Index Por

S&P DOW JONES INDICES DOES NOT GUARANTEE THE ADEQUACY, ACCURACY, TIMELINESS AND/OR THE COMPLETENESS OF THE S&P TOTAL MARKET INDEX OR ANY DATA RELATED THERETO OR ANY COMMUNICATION, INCLUDING BUT NOT LIMITED TO, ORAL OR WRITTEN COMMUNICATION (INCLUDING ELECTRONIC COMMUNICATIONS) WITH RESPECT THERETO. S&P DOW JONES INDICES SHALL NOT BE SUBJECT TO ANY DAMAGES OR LIABILITY FOR ANY ERRORS, OMISSIONS, OR DELAYS THEREIN. S&P DOW JONES INDICES MAKES NO EXPRESS OR IMPLIED WARRANTIES, AND EXPRESSLY DISCLAIMS ALL WARRANTIES, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE OR AS TO RESULTS TO BE OBTAINED BY VANGUARD, OWNERS OF THE TOTAL STOCK MARKET INDEX PORTFOLIO, OR ANY OTHER PERSON OR ENTITY FROM THE USE OF THE S&P TOTAL MARKET INDEX OR WITH RESPECT TO ANY DATA RELATED THERETO. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT WHATSOEVER SHALL S&P DOW JONES INDICES BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES INCLUDING BUT NOT LIMITED TO, LOSS OF PROFITS, TRADING LOSSES, LOST TIME OR GOODWILL, EVEN IF THEY HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, WHETHER IN CONTRACT, TORT, STRICT LIABILITY, OR OTHERWISE. THERE ARE NO THIRD PARTY BENEFICIARIES OF ANY AGREEMENTS OR ARRANGEMENTS BETWEEN S&P DOW JONES INDICES AND VANGUARD, OTHER THAN THE LICENSORS OF S&P DOW JONES INDICES.

This page intentionally left blank.

This page intentionally left blank.

This page intentionally left blank.

The People Who Govern Your Fund

The trustees of your mutual fund are there to see that the fund is operated and managed in your best interests since, as a shareholder, you are a part owner of the fund. Your fund's trustees also serve on the board of directors of The Vanguard Group, Inc., which is owned by the Vanguard funds and provides services to them.

A majority of Vanguard's board members are independent, meaning that they have no affiliation with Vanguard or the funds they oversee, apart from the sizable personal investments they have made as private individuals. The independent board members have distinguished backgrounds in business, academia, and public service. Each of the trustees and executive officers oversees 208 Vanguard funds.

Information for each trustee and executive officer of the fund appears below. That information, as well as the Vanguard fund count, is as of the date on the cover of this fund report. The mailing address of the trustees and officers is PO. Box 876, Valley Forge, PA 19482. More information about the trustees is in the *Statement of Additional Information*, which can be obtained, without charge, by contacting Vanguard at 800-662-7447, or online at vanguard.com.

Interested Trustee¹

Mortimer J. Buckley

Born in 1969. Trustee since January 2018. Principal occupation(s) during the past five years and other experience: chairman of the board (2019-present) of Vanguard and of each of the investment companies served by Vanguard; chief executive officer (2018-present) of Vanguard; chief executive officer, president, and trustee (2018-present) of each of the investment companies served by Vanguard; president and director (2017-present) of Vanguard; and president (2018-present) of Vanguard Marketing Corporation. Chief investment officer (2013-2017), managing director (2002–2017), head of the Retail Investor Group (2006-2012), and chief information officer (2001-2006) of Vanguard. Member of the board of governors of the Investment Company Institute and the board of governors of FINRA.

Independent Trustees

Tara Bunch

Born in 1962. Trustee since November 2021. Principal occupation(s) during the past five years and other experience: head of global operations at Airbnb (2020–present). Vice president of AppleCare (2012–2020). Member of the board of directors of Out & Equal, the advisory board of the University of California, Berkeley School of Engineering, and the advisory board of Santa Clara University's Leavey School of Business.

Emerson U. Fullwood

Born in 1948. Trustee since January 2008. Principal occupation(s) during the past five years and other experience: executive chief staff and marketing officer for North America and corporate vice president (retired 2008) of Xerox Corporation (document management products and services). Former president of the Worldwide Channels Group, Latin America, and Worldwide Customer Service and executive chief staff officer of Developing Markets of Xerox. Executive in residence and 2009–2010 Distinguished Minett Professor at the Rochester Institute of Technology. Member of the board of directors of the University of Rochester Medical Center, the Monroe Community College Foundation, the United Way of Rochester, North Carolina A&T University, Roberts Wesleyan College, and the Rochester Philharmonic Orchestra. Trustee of the University of Rochester.

F. Joseph Loughrey

Born in 1949. Trustee since October 2009. Principal occupation(s) during the past five years and other experience: president and chief operating officer (retired 2009) and vice chairman of the board (2008–2009) of Cummins Inc. (industrial machinery). Director of the V Foundation. Member of the advisory council for the College of Arts and Letters at the University of Notre Dame. Chairman of the board of Saint Anselm College.

Mark Loughridge

Born in 1953. Trustee since March 2012. Principal occupation(s) during the past five years and other experience: senior vice president and chief financial officer (retired 2013) of IBM (information technology services). Fiduciary member of IBM's Retirement Plan Committee (2004–2013), senior vice president and general manager (2002–2004) of IBM Global Financing, vice president and controller (1998–2002) of IBM, and a variety of other prior management roles at IBM. Member of the Council on Chicago Booth.

Scott C. Malpass

Born in 1962. Trustee since March 2012. Principal occupation(s) during the past five years and other experience: co-founder and managing partner (2022–present) of Grafton Street Partners (investment advisory firm). Chief investment officer (retired 2020) and vice president (retired 2020) of the University of Notre Dame. Chair of the board of Catholic Investment Services, Inc. (investment advisors). Member of the board of superintendence of the Institute for the Works of Religion, the Notre Dame 403(b) Investment Committee, and the board of directors of Paxos Trust Company (finance).

Deanna Mulligan

Born in 1963. Trustee since January 2018. Principal occupation(s) during the past five years and other experience: chief executive officer of Purposeful (advisory firm for CEOs and C-level executives; 2021–present). Board chair (2020), chief executive officer (2011–2020), and president (2010–2019) of The Guardian Life Insurance Company of America. Chief operating officer (2010–2011) and executive vice president (2008–2010) of Individual Life and Disability of the Guardian Life Insurance Company of America. Director of DuPont. Member of the board of the Economic Club of New York. Trustee of the Partnership for New York City (business leadership), Chief Executives for Corporate Purpose, and the NewYork-Presbyterian Hospital.

André F. Perold

Born in 1952. Trustee since December 2004. Principal occupation(s) during the past five years and other experience: George Gund Professor of Finance and Banking, Emeritus at the Harvard Business School (retired 2011). Chief investment officer and partner of HighVista Strategies (private investment firm). Member of the board of RIT Capital Partners (investment firm).

Sarah Bloom Raskin

Born in 1961. Trustee since January 2018. Principal occupation(s) during the past five years and other experience: deputy secretary (2014–2017) of the United States Department of the Treasury. Governor (2010–2014) of the Federal Reserve Board. Commissioner (2007–2010) of financial regulation for the State of Maryland. Colin W. Brown Distinguished Professor of the Practice of Law, Duke Law School (2021–present); Rubenstein Fellow, Duke University (2017–2020); Distinguished Fellow of the Global Financial Markets Center, Duke Law School (2020–2022); and Senior Fellow, Duke Center on Risk (2020–present). Partner of Kaya Partners (climate policy advisory services). Member of the board of directors of Arcadia (energy solution technology).

Grant Reid

Born in 1959. Trustee since July 2023. Principal occupation(s) during the past five years and other experience: chief executive officer and president (2014–2022) and member of the board of directors (2015–2022) of Mars, Incorporated (multinational manufacturer). Member of the board of directors of Marriott International, Inc. Chair of Agribusiness Task Force, Sustainable Markets Initiative.

David Thomas

Born in 1956. Trustee since July 2021. Principal occupation(s) during the past five years and other experience: president of Morehouse College (2018–present). Professor of business administration, emeritus at Harvard University (2017–2018). Dean (2011–2016) and professor of management (2016–2017) at the Georgetown University McDonough School of Business. Director of DTE Energy Company. Trustee of Common Fund.

Peter F. Volanakis

Born in 1955. Trustee since July 2009. Principal occupation(s) during the past five years and other experience: president and chief operating officer (retired 2010) of Corning Incorporated (communications equipment) and director of Corning

Incorporated (2000–2010) and Dow Corning (2001–2010). Director (2012) of SPX Corporation (multi-industry manufacturing). Overseer of the Amos Tuck School of Business Administration, Dartmouth College (2001–2013). Member of the BMW Group Mobility Council.

Executive Officers

Jacqueline Angell

Born in 1974. Principal occupation(s) during the past five years and other experience: principal of Vanguard. Chief compliance officer (November 2022–present) of Vanguard and of each of the investment companies served by Vanguard. Chief compliance officer (2018–2022) and deputy chief compliance officer (2017–2019) of State Street.

Christine M. Buchanan

Born in 1970. Principal occupation(s) during the past five years and other experience: principal of Vanguard. Chief financial officer (2021–present) and treasurer (2017–2022) of each of the investment companies served by Vanguard. Partner (2005–2017) at KPMG (audit, tax, and advisory services).

John Galloway

Born in 1973. Principal occupation(s) during the past five years and other experience: principal of Vanguard. Investment stewardship officer (September 2020–present) of each of the investment companies served by Vanguard. Head of Investor Advocacy (February 2020–present) and head of Marketing Strategy and Planning (2017–2020) at Vanguard. Special assistant to the President of the United States (2015).

Ashley Grim

Born in 1984. Principal occupation(s) during the past five years and other experience: treasurer (February 2022–present) of each of the investment companies served by Vanguard. Fund transfer agent controller (2019–2022) and director of Audit Services (2017–2019) at Vanguard. Senior manager (2015–2017) at PriceWaterhouseCoopers (audit and assurance, consulting, and tax services).

Jodi Miller

Born in 1980. Principal occupation(s) during the past five years and other experience: principal of Vanguard. Finance director (2022–present) of each of the investment companies served by Vanguard. Head of Enterprise Investment Services (2020–present), head of Retail Client Services and Operations (2020–2022), and head of Retail Strategic Support (2018–2020) at Vanguard.

Anne E. Robinson

Born in 1970. Principal occupation(s) during the past five years and other experience: general counsel (2016–present) of Vanguard. Secretary (2016–present) of Vanguard and of each of the investment companies served by Vanguard. Managing director (2016–present) of Vanguard. Managing director and general counsel of Global Cards and Consumer Services (2014–2016) at Citigroup. Counsel (2003–2014) at American Express. Nonexecutive director (2022–present) of the board of National Grid (energy).

Michael Rollings

Born in 1963. Principal occupation(s) during the past five years and other experience: finance director (2017–present) and treasurer (2017) of each of the investment companies served by Vanguard. Managing director (2016–present) of Vanguard. Chief financial officer (2016–present) of Vanguard. Director (2016–present) of Vanguard Marketing Corporation. Executive vice president and chief financial officer (2006–2016) of MassMutual Financial Group.

Vanguard Senior Management Team

Matthew Benchener	Thomas M. Rampulla
Joseph Brennan	Karin A. Risi
Mortimer J. Buckley	Anne E. Robinson
Gregory Davis	Michael Rollings
John James	Nitin Tandon
Chris D. McIsaac	Lauren Valente

Vanguard

Connect with Vanguard[®] > vanguard.com

Fund Information > 800-662-7447

Annuity and Insurance Services > 800-522-5555

Institutional Investor Services > 800-523-1036 Text Telephone for People

Who Are Deaf or Hard of Hearing > 800-749-7273

This material may be used in conjunction with the offering of shares of any Vanguard fund only if preceded or accompanied by the fund's current prospectus.

All comparative mutual fund data are from Morningstar, Inc., unless otherwise noted.

You can obtain a free copy of Vanguard's proxy voting guidelines by visiting vanguard.com/proxyreporting or by calling Vanguard at 800-662-2739. The guidelines are also available from the SEC's website, www.sec.gov. In addition, you may obtain a free report on how your fund voted the proxies for securities it owned during the 12 months ended June 30. To get the report, visit either vanguard.com/proxyreporting or www.sec.gov.

You can review information about your portfolio on the SEC's website, and you can receive copies of this information, for a fee, by sending a request via email addressed to publicinfo@sec.gov.

Source for Bloomberg indexes: Bloomberg Index Services Limited. Copyright 2024, Bloomberg. All rights reserved.

© 2024 The Vanguard Group, Inc. All rights reserved. Vanguard Marketing Corporation, Distributor.

Q690TSMI 022024

Vanguard

Annual Report | December 31, 2023

Vanguard Variable Insurance Funds

Equity Index Portfolio

See the inside front cover for important information about your fund's annual and semiannual shareholder reports.

Important information about shareholder reports

Beginning in July 2024, amendments adopted by the Securities and Exchange Commission will substantially impact the design, content, and transmission of shareholder reports. Shareholder reports will provide key fund information in a clear and concise format and must be mailed to each shareholder that has not elected to receive the reports electronically. Financial statements will no longer be included in the shareholder report but will be available at vanguard.com, can be mailed upon request, or can be accessed on the SEC's website at www.sec.gov.

You may elect to receive shareholder reports and other communications from the fund electronically by contacting your financial intermediary (such as a broker-dealer or bank) or, if you invest directly with the fund, by calling Vanguard at one of the phone numbers on the back cover of this report or by logging on to vanguard.com.

Contents

Your Portfolio's Performance at a Glance1
About Your Portfolio's Expenses2
Performance Summary
Financial Statements5

Your Portfolio's Performance at a Glance

• The financial markets delivered robust returns for the 12 months ended December 31, 2023. The Equity Index Portfolio returned 26.11%, in line with the 26.29% return of its benchmark, the Standard & Poor's 500 Index.

• With inflation continuing to ease, a number of major central banks slowed and eventually stopped hiking interest rates. Global growth, employment, and consumer spending showed resilience, but the prospect of rates remaining high for an extended period spurred volatility at times. Toward year end, however, global stocks and bonds rallied as falling inflation and softening economic growth raised market expectations for rate cuts in 2024.

• Within the U.S. equity market, large-cap stocks outpaced small-caps during the period, and growth stocks outpaced value by a substantial margin. Within the benchmark index, most sectors had double-digit gains, with information technology stocks accounting for more than half of the index's total return. Only energy and utilities posted negative returns.

• For the 10 years ended December 31, 2023, the portfolio recorded an average annual return of 11.88%, in line with its benchmark average of 12.03%.

• Please note that the portfolio's returns may be different from those in variable annuity products that invest in the portfolio, which take insurance-related expenses into account.

Market Barometer

	Average Annual Total Returns Periods Ended December 31, 2023		
	One Year	Three Years	Five Years
Stocks			
Russell 1000 Index (Large-caps)	26.53%	8.97%	15.52%
Russell 2000 Index (Small-caps)	16.93	2.22	9.97
Russell 3000 Index (Broad U.S. market)	25.96	8.54	15.16
FTSE All-World ex US Index (International)	15.82	1.98	7.52
Bonds			
Bloomberg U.S. Aggregate Float Adjusted Index (Broad taxable market)	5.60%	-3.33%	1.17%
Bloomberg Municipal Bond Index (Broad tax-exempt market)	6.40	-0.40	2.25
FTSE Three-Month U.S. Treasury Bill Index	5.26	2.24	1.91
СРІ			
Consumer Price Index	3.35%	5.60%	4.07%

About Your Portfolio's Expenses

As a shareholder of the portfolio, you incur ongoing costs, which include costs for portfolio management, administrative services, and shareholder reports (like this one), among others. Operating expenses, which are deducted from a portfolio's gross income, directly reduce the investment return of the portfolio.

A portfolio's expenses are expressed as a percentage of its average net assets. This figure is known as the expense ratio. The following examples are intended to help you understand the ongoing costs (in dollars) of investing in your portfolio and to compare these costs with those of other mutual funds. The examples are based on an investment of \$1,000 made at the beginning of the period shown and held for the entire period.

The accompanying table illustrates your portfolio's costs in two ways:

• **Based on actual portfolio return.** This section helps you to estimate the actual expenses that you paid over the period. The "Ending Account Value" shown is derived from the portfolio's actual return, and the third column shows the dollar amount that would have been paid by an investor who started with \$1,000 in the portfolio. You may use the information here, together with the amount you invested, to estimate the expenses that you paid over the period.

To do so, simply divide your account value by \$1,000 (for example, an \$8,600 account value divided by \$1,000 = 8.6), then multiply the result by the number given for your portfolio under the heading "Expenses Paid During Period."

• Based on hypothetical 5% yearly return. This section is intended to help you compare your portfolio's costs with those of other mutual funds. It assumes that the portfolio had a yearly return of 5% before expenses, but that the expense ratio is unchanged. In this case—because the return used is not the portfolio's actual return—the results do not apply to your investment. The example is useful in making comparisons because the Securities and Exchange Commission requires all mutual funds to calculate expenses based on a 5% return. You can assess your portfolio's costs by comparing this hypothetical example with the hypothetical examples that appear in shareholder reports of other funds.

Note that the expenses shown in the table are meant to highlight and help you compare *ongoing* costs only and do not reflect transaction costs incurred by the portfolio for buying and selling securities. The portfolio's expense ratio does not reflect additional fees and expenses associated with the annuity or life insurance program through which you invest.

The calculations assume no shares were bought or sold during the period. Your actual costs may have been higher or lower, depending on the amount of your investment and the timing of any purchases or redemptions.

You can find more information about the portfolio's expenses, including annual expense ratios, in the Financial Statements section of this report. For additional information on operating expenses and other shareholder costs, please refer to your portfolio's current prospectus.

Six Months Ended December 31, 2023

Equity Index Portfolio	Beginning Account Value 6/30/2023	Ending Account Value 12/31/2023	Expenses Paid During Period
Based on Actual Portfolio Return	\$1,000.00	\$1,079.60	\$0.73
Based on Hypothetical 5% Yearly Return	1,000.00	1,024.50	0.71


The calculations are based on expenses incurred in the most recent six-month period. The portfolio's annualized six-month expense ratio for that period is 0.14%. The dollar amounts shown as "Expenses Paid" are equal to the annualized expense ratio multiplied by the average account value over the period, multiplied by the number of days in the most recent six-month period, then divided by the number of days in the most recent 12-month period (184/365).

Equity Index Portfolio

Performance Summary

All of the returns in this report represent past performance, which is not a guarantee of future results that may be achieved by the portfolio. (Current performance may be lower or higher than the performance data cited. For performance data current to the most recent month-end, visit our website at vanguard.com/performance.) Note, too, that both investment returns and principal value can fluctuate widely, so an investor's shares, when sold, could be worth more or less than their original cost. The returns shown do not reflect taxes that a shareholder would pay on portfolio distributions or on the sale of portfolio shares. Nor do the returns reflect fees and expenses associated with the annuity or life insurance program through which a shareholder invests. If these fees and expenses were included, the portfolio's returns would be lower.

Cumulative Performance: December 31, 2013, Through December 31, 2023 Initial Investment of \$10,000



	Average Annual Total Returns Periods Ended December 31, 2023				
	One Year	Five Years	Ten Years	Final Value of a \$10,000 Investment	
Equity Index Portfolio	26.11%	15.52%	11.88%	\$30,719	
······ S&P 500 Index	26.29	15.69	12.03	31,149	
Dow Jones U.S. Total Stock Market Float Adjusted Index	26.06	15.05	11.40	29,422	

Portfolio Allocation

As of December 31, 2023

8.6%
10.8
6.2
3.9
13.0
12.6
8.8
28.9
2.4
2.5
2.3

The table reflects the portfolio's investments, except for short-term investments and derivatives. Sector categories are based on the Global Industry Classification Standard ("GICS"), except for the "Other" category (if applicable), which includes securities that have not been provided a GICS classification as of the effective reporting period.

The portfolio may invest in derivatives (such as futures and swap contracts) for various reasons, including, but not limited to, attempting to remain fully invested and tracking its target index as closely as possible.

The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard and Poor's, a division of McGraw-Hill Companies, Inc. ("S&P"), and is licensed for use by Vanguard. Neither MSCI, S&P nor any third party involved in making or compiling the GICS or any GICS classification makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of its affiliates or any third party involved in making or compiling the GICS or any GICS classification have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

Financial Statements

Schedule of Investments

As of December 31, 2023

The portfolio files its complete schedule of portfolio holdings with the Securities and Exchange Commission (SEC) for the first and third quarters of each fiscal year as an exhibit to its reports on Form N-PORT. The portfolio's Form N-PORT reports are available on the SEC's website at www.sec.gov.

		Shares	Market Value• (\$000)
Со	ommon Stocks (99.4%)		
	ommunication Services (8.5%)		
*	Alphabet Inc. Class A	1,355,291	189,321
×	Meta Platforms Inc. Class A	508,331	179,929
÷	Alphabet Inc. Class C	1,140,701	160,759
÷	Netflix Inc.	100,238	48,804
	Comcast Corp. Class A	919,703	40,329
	Walt Disney Co.	419,073	37,838
	Verizon Communications Inc.	962,820	36,298
	AT&T Inc.	1,637,519	27,478
	T-Mobile US Inc.	116,523	18,682
÷	Charter Communications Inc. Class A	23,014	8,945
	Electronic Arts Inc.	55,997	7,661
ł	Take-Two Interactive Software Inc.	36,242	5,833
÷	Warner Bros Discovery Inc.	508,626	5,788
	Omnicom Group Inc.	45,274	3,917
•	Live Nation Entertainment Inc.	32,539	3,046
	Interpublic Group of Cos. Inc.	87,994	2,872
•	Match Group Inc.	62,175	2,269
	News Corp. Class A	87,101	2,138
	Fox Corp. Class A	56,421	1,674
I	Paramount Global Class B	109,997	1,627
	Fox Corp. Class B	30,418	841
	News Corp. Class B	26,124	672
_			786,721
Co	onsumer Discretionary (10.8%)	0,000,075	010 440
	Amazon.com Inc.	2,082,675	316,442
	Tesla Inc.	633,375	157,382
	Home Depot Inc.	229,033	79,371
	McDonald's Corp. NIKE Inc. Class B	166,131	49,260
	Lowe's Cos. Inc.	280,335	30,436
	Booking Holdings Inc.	132,171	29,415
	Starbucks Corp.	7,992 261,705	28,349 25,126
	TJX Cos. Inc.	261,993	23,120
	Chipotle Mexican Grill Inc. Class A	6,287	14,378
	Airbnb Inc. Class A	99,585	14,378
	Lululemon Athletica Inc.	26,379	13,487
	O'Reilly Automotive Inc.	13,553	12,876
	Marriott International Inc. Class A	56,521	12,746
	General Motors Co.	313,795	11,272
	Ford Motor Co.	901,127	10,985
	Ross Stores Inc.	77,600	10,739
	Hilton Worldwide Holdings Inc.	58,769	10,701
	DR Horton Inc.	69,066	10,497
ł	AutoZone Inc.	4,041	10,448
	Lennar Corp. Class A	56,426	8,410
	Yum! Brands Inc.	64,175	8,385
	Royal Caribbean Cruises Ltd.	53,915	6,981
	Aptiv plc	64,873	5,820
	Ulta Beauty Inc.	11,261	5,518
	Tractor Supply Co.	24,730	5,318
	eBay Inc.	118,732	5,179
	PulteGroup Inc.	49,323	5,091
÷	NVR Inc.	43,323	5,089
	Expedia Group Inc.	30,500	4,630
	Exposis Group ino.		
	Darden Bestaurants Inc	27508	4 570
	Darden Restaurants Inc. Garmin Ltd.	27,508 35,058	4,520 4,506

			Market
		Shares	Value* (\$000)
*	Carnival Corp.	230,722	4,278
	Las Vegas Sands Corp.	84,390	4,153
	Pool Corp.	8,847	3,527
	Best Buy Co. Inc.	44,401	3,476
	Domino's Pizza Inc.	7,979	3,289
*	LKQ Corp.	61,423	2,935
*	MGM Resorts International CarMax Inc	62,513	2,793
*	Cariviax Inc. Caesars Entertainment Inc.	36,332	2,788
	Bath & Body Works Inc.	49,417 52,008	2,317 2,245
*	Etsy Inc.	27,391	2,245
	Wynn Resorts Ltd.	22,081	2,012
*	Norwegian Cruise Line Holdings Ltd.	97,251	1,949
	Tapestry Inc.	52,418	1,930
	BorgWarner Inc.	53,745	1,927
	Whirlpool Corp.	12,551	1,528
	Hasbro Inc.	29,865	1,525
	VF Corp.	75,544	1,420
J	Ralph Lauren Corp. Class A	9,077	1,309
*	Mohawk Industries Inc.	12,068	1,249
	Lennar Corp. Class B	1,025	137
Сс	onsumer Staples (6.1%)		994,947
	Procter & Gamble Co.	539,700	79,088
	Costco Wholesale Corp.	101,395	66,929
	PepsiCo Inc.	314,858	53,476
	Coca-Cola Co.	891,059	52,510
	Walmart Inc.	326,691	51,503
	Philip Morris International Inc.	355,503	33,446
	Mondelez International Inc. Class A	311,481	22,561
	Altria Group Inc. Target Corp.	405,038 105,721	16,339
	Colgate-Palmolive Co.	188,630	15,057 15,036
*	Monster Beverage Corp.	169,275	9,752
	Kimberly-Clark Corp.	77,412	9,406
	Constellation Brands Inc. Class A	37,004	8,946
	Archer-Daniels-Midland Co.	122,277	8,831
	General Mills Inc.	133,258	8,680
	Kenvue Inc.	394,682	8,498
	Sysco Corp.	115,360	8,436
	Estee Lauder Cos. Inc. Class A	53,259	7,789
	Keurig Dr Pepper Inc.	230,535	7,681
	Kroger Co.	151,419	6,921
*	Dollar General Corp.	50,279	6,835
	Dollar Tree Inc.	47,889	6,803
	Kraft Heinz Co.	182,396	6,745
	Hershey Co. Church & Dwight Co. Inc.	34,355 56,491	6,405 5,342
	Walgreens Boots Alliance Inc.	164,375	4,292
	Clorox Co.	28,364	4,044
	McCormick & Co. Inc. (Non-Voting)	57,581	3,940
	Lamb Weston Holdings Inc.	33,151	3,583
	Tyson Foods Inc. Class A	65,160	3,502
	Kellanova	60,426	3,378
	Bunge Global SA	33,237	3,355
	Conagra Brands Inc.	109,410	3,136
	J M Smucker Co.	24,379	3,081
	Molson Coors Beverage Co. Class B	42,342	2,592
	Brown-Forman Corp. Class B	41,986	2,397

	Shares	Market Value• (\$000)
Hormel Foods Corp. Campbell Soup Co.	66,483 44,876	2,135 1,940
	-	564,390
Energy (3.9%) Exxon Mobil Corp.	017271	01 700
Chevron Corp.	917,271 402,002	91,709 59,963
ConocoPhillips	271,822	31,550
Schlumberger NV	327,124	17,024
EOG Resources Inc.	133,570	16,155
Phillips 66	100,777	13,417
Marathon Petroleum Corp.	86,976	12,904
Pioneer Natural Resources Co.	53,402	12,009
Valero Energy Corp.	78,016	10,142
Williams Cos. Inc.	278,831	9,712
ONEOK Inc.	133,554	9,378
Hess Corp. Occidental Petroleum Corp.	63,369 151,325	9,135 9,036
Baker Hughes Co. Class A	230,732	7,886
Kinder Morgan Inc.	443,350	7,821
Halliburton Co.	204,748	7,402
Devon Energy Corp.	146,825	6,651
Diamondback Energy Inc.	40,992	6,357
Targa Resources Corp.	50,981	4,429
Coterra Energy Inc.	172,014	4,390
EQT Corp.	94,084	3,637
Marathon Oil Corp.	133,821	3,233
APA Corp.	70,359 _	2,524 356,464
Financials (12.9%)		550,404
* Berkshire Hathaway Inc. Class B	416,676	148,612
JPMorgan Chase & Co.	662,088	112,621
Visa Inc. Class A	365,039	95,038
Mastercard Inc. Class A Bank of America Corp.	189,640 1,576,846	80,883 53,092
Wells Fargo & Co.	831,733	40,938
S&P Global Inc.	74,196	32,685
Goldman Sachs Group Inc.	74,687	28,812
Morgan Stanley	289,435	26,990
BlackRock Inc.	32,022	25,995
American Express Co.	131,863	24,703
Charles Schwab Corp.	340,825	23,449
Citigroup Inc.	438,352	22,549
Marsh & McLennan Cos. Inc.	112,899	21,391
Progressive Corp.	133,983	21,341
Blackstone Inc. Chubb Ltd.	162,730	21,305 21,114
* Fiserv Inc.	93,424 137,444	18,258
CME Group Inc.	82,432	17,360
Intercontinental Exchange Inc.	131,056	16,832
US Bancorp	356,623	15,435
* PayPal Holdings Inc.	246,935	15,164
PNC Financial Services Group Inc.	91,236	14,128
Moody's Corp.	36,049	14,079
Aon plc Class A	45,865	13,348
Capital One Financial Corp.	87,268	11,443
Truist Financial Corp.	305,475	11,278
Arthur J Gallagher & Co.	49,444	11,119
American International Group Inc. MSCI Inc. Class A	160,877 18,105	10,899 10,241
Aflac Inc.	121,882	10,241
Travelers Cos. Inc.	52,346	9,971
MetLife Inc.	142,515	9,425
Bank of New York Mellon Corp.	176,293	9,176
Ameriprise Financial Inc.	23,198	8,811
Prudential Financial Inc.	82,765	8,584
Allstate Corp.	59,915	8,387
Fidelity National Information Services Inc.	135,737	8,154

			Market
		Channa	Value•
		Shares	(\$000)
*	Discover Financial Services Arch Capital Group Ltd.	57,201 85,407	6,429 6,343
	Willis Towers Watson plc	23,622	5,698
	Hartford Financial Services Group Inc.	68,802	5,530
	T. Rowe Price Group Inc.	51,118	5,505
	State Street Corp. Fifth Third Bancorp	70,591 156,060	5,468 5,383
	M&T Bank Corp.	38,048	5,216
J	Raymond James Financial Inc.	43,031	4,798
*	FleetCorTechnologies Inc.	16,518	4,668
	Nasdaq Inc. Cboe Global Markets Inc.	77,939 24,162	4,531 4,314
	Huntington Bancshares Inc.	331,368	4,215
	FactSet Research Systems Inc.	8,689	4,145
	Regions Financial Corp.	212,766	4,123
	Northern Trust Corp.	47,436	4,003
	Principal Financial Group Inc. Brown & Brown Inc.	50,174 54,226	3,947 3,856
	Cincinnati Financial Corp.	35,888	3,850
	Synchrony Financial	94,654	3,615
	Citizens Financial Group Inc.	106,662	3,535
	Everest Group Ltd.	9,944	3,516
	W R Berkley Corp.	46,658	3,300 3,087
	KeyCorp Loews Corp.	214,390 41,881	2,914
	Jack Henry & Associates Inc.	16,726	2,733
	MarketAxess Holdings Inc.	8,699	2,548
	Globe Life Inc.	19,587	2,384
	Assurant Inc. Franklin Resources Inc.	12,030 64,791	2,027 1,930
	Invesco Ltd.	103,388	1,844
	Comerica Inc.	30,128	1,681
	Zions Bancorp NA	33,798	1,483
He	alth Care (12.5%)		1,189,715
He	alth Care (12.5%) UnitedHealth Group Inc.	211,820	
He	alth Care (12.5%) UnitedHealth Group Inc. Eli Lilly & Co.	211,820 182,622	1,189,715 111,517 106,454
He	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson	182,622 551,289	111,517 106,454 86,409
He	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc.	182,622 551,289 580,312	111,517 106,454 86,409 63,266
He	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc.	182,622 551,289 580,312 404,326	111,517 106,454 86,409 63,266 62,658
He	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc.	182,622 551,289 580,312	111,517 106,454 86,409 63,266
He	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc.	182,622 551,289 580,312 404,326 88,480	111,517 106,454 86,409 63,266 62,658 46,964
He	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc.	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301
He	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp.	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840
He	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp. Intuitive Surgical Inc.	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600 80,623	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840 27,199
He	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp.	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840
He *	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp. Intuitive Surgical Inc. Elevance Health Inc. Medtronic plc Vertex Pharmaceuticals Inc.	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600 80,623 53,808 304,656 59,012	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840 27,199 25,374 25,098 24,011
Не * *	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp. Intuitive Surgical Inc. Elevance Health Inc. Medtronic plc Vertex Pharmaceuticals Inc. Bristol-Myers Squibb Co.	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600 80,623 53,808 304,656 59,012 465,967	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840 27,199 25,374 25,098 24,011 23,909
Не * *	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp. Intuitive Surgical Inc. Elevance Health Inc. Medtronic plc Vertex Pharmaceuticals Inc. Bristol-Myers Squibb Co. CVS Health Corp.	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600 80,623 53,808 304,656 59,012 465,967 294,147	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840 27,199 25,374 25,098 24,011 23,909 23,226
Не * *	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp. Intuitive Surgical Inc. Elevance Health Inc. Medtronic plc Vertex Pharmaceuticals Inc. Bristol-Myers Squibb Co. CVS Health Corp. Stryker Corp.	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600 80,623 53,808 304,656 59,012 465,967 294,147 77,421	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840 27,199 25,374 25,098 24,011 23,909 23,226 23,184
не * *	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp. Intuitive Surgical Inc. Elevance Health Inc. Medtronic plc Vertex Pharmaceuticals Inc. Bristol-Myers Squibb Co. CVS Health Corp.	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600 80,623 53,808 304,656 59,012 465,967 294,147	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840 27,199 25,374 25,098 24,011 23,909 23,226
+ + *	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp. Intuitive Surgical Inc. Elevance Health Inc. Medtronic plc Vertex Pharmaceuticals Inc. Bristol-Myers Squibb Co. CVS Health Corp. Stryker Corp. Gilead Sciences Inc. Regeneron Pharmaceuticals Inc. Zoetis Inc. Class A	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600 80,623 53,808 304,656 59,012 465,967 294,147 77,421 285,353 24,533 105,144	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840 27,199 25,374 25,098 24,011 23,909 23,226 23,184 23,116 21,547 20,752
++++++++++++++++++++++++++++++++++++++	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp. Intuitive Surgical Inc. Elevance Health Inc. Medtronic plc Vertex Pharmaceuticals Inc. Bristol-Myers Squibb Co. CVS Health Corp. Stryker Corp. Gilead Sciences Inc. Regeneron Pharmaceuticals Inc. Zoetis Inc. Class A Cigna Group	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600 80,623 53,808 304,656 59,012 465,967 294,147 77,421 285,353 24,533 105,144 67,014	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840 27,199 25,374 25,098 24,011 23,909 23,226 23,184 23,116 21,547 20,752 20,067
++++++++++++++++++++++++++++++++++++++	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp. Intuitive Surgical Inc. Elevance Health Inc. Medtronic plc Vertex Pharmaceuticals Inc. Bristol-Myers Squibb Co. CVS Health Corp. Stryker Corp. Gilead Sciences Inc. Regeneron Pharmaceuticals Inc. Zoetis Inc. Class A Cigna Group Boston Scientific Corp.	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600 80,623 53,808 304,656 59,012 465,967 294,147 77,421 285,353 24,533 105,144 67,014 335,257	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840 27,199 25,374 25,098 24,011 23,909 23,226 23,184 23,116 21,547 20,752 20,067 19,381
+ + + + + + + + + + + + + + + + + + +	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp. Intuitive Surgical Inc. Elevance Health Inc. Medtronic plc Vertex Pharmaceuticals Inc. Bristol-Myers Squibb Co. CVS Health Corp. Stryker Corp. Gilead Sciences Inc. Regeneron Pharmaceuticals Inc. Zoetis Inc. Class A Cigna Group Boston Scientific Corp. Becton Dickinson & Co.	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600 80,623 53,808 304,656 59,012 465,967 294,147 77,421 285,353 24,533 105,144 67,014 335,257 66,424	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840 27,199 25,374 25,098 24,011 23,909 23,226 23,184 23,116 21,547 20,067 19,381 16,196
He * *	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp. Intuitive Surgical Inc. Elevance Health Inc. Medtronic plc Vertex Pharmaceuticals Inc. Bristol-Myers Squibb Co. CVS Health Corp. Stryker Corp. Gilead Sciences Inc. Regeneron Pharmaceuticals Inc. Zoetis Inc. Class A Cigna Group Boston Scientific Corp.	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600 80,623 53,808 304,656 59,012 465,967 294,147 77,421 285,353 24,533 105,144 67,014 335,257	111,517 106,454 86,409 62,658 46,964 43,739 37,229 35,301 34,840 27,199 25,374 25,098 24,011 23,909 23,226 23,184 23,116 21,547 20,752 20,067 19,381
He * *	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp. Intuitive Surgical Inc. Elevance Health Inc. Medtronic plc Vertex Pharmaceuticals Inc. Bristol-Myers Squibb Co. CVS Health Corp. Stryker Corp. Gilead Sciences Inc. Regeneron Pharmaceuticals Inc. Zoetis Inc. Class A Cigna Group Boston Scientific Corp. Becton Dickinson & Co. McKesson Corp. Humana Inc. HCA Healthcare Inc.	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600 80,623 53,808 304,656 59,012 465,967 294,147 77,421 285,353 24,533 105,144 67,014 335,257 66,424 30,483 28,205 45,383	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840 27,199 25,374 25,098 24,011 23,909 23,226 23,184 23,116 21,547 20,752 20,067 19,381 16,196 14,113 12,913 12,284
He * * *	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp. Intuitive Surgical Inc. Elevance Health Inc. Medtronic plc Vertex Pharmaceuticals Inc. Bristol-Myers Squibb Co. CVS Health Corp. Stryker Corp. Gilead Sciences Inc. Regeneron Pharmaceuticals Inc. Zoetis Inc. Class A Cigna Group Boston Scientific Corp. Becton Dickinson & Co. McKesson Corp. Human Inc. HCA Healthcare Inc. Dexcom Inc.	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600 80,623 53,808 304,656 59,012 465,967 294,147 77,421 285,353 24,533 105,144 67,014 335,257 66,424 30,483 28,205 45,383 88,541	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840 27,199 25,374 25,098 24,011 23,909 23,226 23,184 23,116 21,547 20,752 20,067 19,381 16,196 14,113 12,913 12,284 10,987
He - - -	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp. Intuitive Surgical Inc. Elevance Health Inc. Medtronic plc Vertex Pharmaceuticals Inc. Bristol-Myers Squibb Co. CVS Health Corp. Stryker Corp. Gilead Sciences Inc. Regeneron Pharmaceuticals Inc. Zoetis Inc. Class A Cigna Group Boston Scientific Corp. Becton Dickinson & Co. McKesson Corp. Humana Inc. HCA Healthcare Inc. Dexcom Inc. Edwards Lifesciences Corp.	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600 80,623 53,808 304,656 59,012 465,967 294,147 77,421 285,353 24,533 105,144 67,014 335,257 66,424 30,483 28,205 45,383 88,541 138,997	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840 27,199 25,374 25,098 24,011 23,909 23,226 23,184 23,116 21,547 20,752 20,067 19,381 16,196 14,113 12,213 12,284 10,987 10,599
He - - -	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp. Intuitive Surgical Inc. Elevance Health Inc. Medtronic plc Vertex Pharmaceuticals Inc. Bristol-Myers Squibb Co. CVS Health Corp. Stryker Corp. Gilead Sciences Inc. Regeneron Pharmaceuticals Inc. Zoetis Inc. Class A Cigna Group Boston Scientific Corp. Becton Dickinson & Co. McKesson Corp. Humana Inc. HCA Healthcare Inc. Dexcom Inc. Edwards Lifesciences Corp. IDEXX Laboratories Inc.	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600 80,623 53,808 304,656 59,012 465,967 294,147 77,421 285,353 24,533 105,144 67,014 335,257 66,424 30,483 28,205 45,383 88,541 138,997 19,040	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840 27,199 25,374 25,098 24,011 23,909 23,226 23,184 23,116 21,547 20,752 20,067 19,381 16,196 14,113 12,913 12,284 10,987 10,599 10,568
He - - - -	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp. Intuitive Surgical Inc. Elevance Health Inc. Medtronic plc Vertex Pharmaceuticals Inc. Bristol-Myers Squibb Co. CVS Health Corp. Stryker Corp. Gilead Sciences Inc. Regeneron Pharmaceuticals Inc. Zoetis Inc. Class A Cigna Group Boston Scientific Corp. Becton Dickinson & Co. McKesson Corp. Humana Inc. HCA Healthcare Inc. Dexcom Inc. Edwards Lifesciences Corp.	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600 80,623 53,808 304,656 59,012 465,967 294,147 77,421 285,353 24,533 105,144 67,014 335,257 66,424 30,483 28,205 45,383 88,541 138,997	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840 27,199 25,374 25,098 24,011 23,909 23,226 23,184 23,116 21,547 20,752 20,067 19,381 16,196 14,113 12,213 12,284 10,987 10,599
He - - -	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp. Intuitive Surgical Inc. Elevance Health Inc. Medtronic plc Vertex Pharmaceuticals Inc. Bristol-Myers Squibb Co. CVS Health Corp. Stryker Corp. Gilead Sciences Inc. Regeneron Pharmaceuticals Inc. Zoetis Inc. Class A Cigna Group Boston Scientific Corp. Becton Dickinson & Co. McKesson Corp. Humana Inc. HCA Healthcare Inc. Dexcom Inc. Edwards Lifesciences Corp. IDEXX Laboratories Inc. Agilent Technologies Inc. Centene Corp.	182,622 551,289 580,312 404,326 88,480 397,375 1,293,107 122,565 150,600 80,623 53,808 304,656 59,012 465,967 294,147 77,421 285,353 24,533 105,144 67,014 335,257 66,424 30,483 28,205 45,383 88,541 138,997 19,040 41,929 67,054 122,219	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840 27,199 25,374 25,098 24,011 23,909 23,226 23,184 23,116 21,547 20,752 20,067 19,381 16,196 14,113 12,913 12,284 10,987 10,568 9,702 9,323 9,070
He - - - - - - -	UnitedHealth Group Inc. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. AbbVie Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Pfizer Inc. Amgen Inc. Danaher Corp. Intuitive Surgical Inc. Elevance Health Inc. Medtronic plc Vertex Pharmaceuticals Inc. Bristol-Myers Squibb Co. CVS Health Corp. Stryker Corp. Gilead Sciences Inc. Regeneron Pharmaceuticals Inc. Zoetis Inc. Class A Cigna Group Boston Scientific Corp. Becton Dickinson & Co. McKesson Corp. Humana Inc. HCA Healthcare Inc. Dexcom Inc. Edwards Lifesciences Corp. IDEXX Laboratories Inc. IQVIA Holdings Inc. Agilent Technologies Inc.	182,622 551,289 580,312 404,326 88,480 397,375 1,233,107 122,565 150,600 80,623 53,808 304,656 59,012 465,967 294,147 77,421 285,353 24,533 105,144 67,014 335,257 66,424 30,483 28,205 45,383 88,541 138,997 19,040 41,929 67,054	111,517 106,454 86,409 63,266 62,658 46,964 43,739 37,229 35,301 34,840 27,199 25,374 25,098 24,011 23,909 23,226 23,184 23,116 21,547 20,752 20,067 19,381 16,196 14,113 12,913 12,284 10,987 10,599 10,568 9,702 9,323

			Market Value•
		Shares	(\$000)
* Moderna	Inc.	75,935	7,552
GE Health	nCare Technologies Inc.	89,673	6,933
* Mettler-To	bledo International Inc.	4,974	6,033
	rmaceutical Services Inc.	16,939	5,965
	Biomet Holdings Inc.	47,837	5,822
ResMed		33,711	5,799
* Illumina li	Health Inc.	56,391	5,684 5,060
STERIS p		36,338 22,655	5,060 4,981
	ealthcare Inc.	13,361	4,827
	ternational Inc.	116,067	4,487
* Align Tech	nnology Inc.	16,278	4,460
* Waters C	orp.	13,539	4,457
	y Corp. of America Holdings	19,428	4,416
Cooper C		11,347	4,294
* Hologic Ir		56,101	4,008
	agnostics Inc.	25,690	3,542
* Insulet Co Revvity Ir	•	16,010 28,221	3,474 3,085
Viatris Inc		275,267	2,981
Bio-Techr		36,142	2,789
	liver Laboratories International Inc.	11,735	2,774
Teleflex Ir		10,784	2,689
* Incyte Co	rp.	42,746	2,684
* Henry Sc		30,024	2,273
	Health Services Inc. Class B	13,961	2,128
Catalent I		41,321	1,857
	Y SIRONA Inc.	48,765	1,736
* DaVita In	aboratories Inc. Class A	4,820	1,556
Davila III	2.	12,285	1,287
Industrials (8	0 00/		1,157,054
Caterpilla		116,823	34,541
	cific Corp.	139,611	34,291
* Boeing C		130,237	33,948
General E	electric Co.	249,259	31,813
Honeywe	II International Inc.	150,960	31,658
	nologies Inc.	471,309	29,019
RTX Corp		329,286	27,706
	arcel Service Inc. Class B	165,636	26,043
Deere &	Lo. I Martin Corp.	61,334 50,559	24,526
Eaton Co		91,431	22,915 22,018
	c Data Processing Inc.	94,181	21,941
	ol Works Inc.	62,710	16,426
CSX Corp		452,659	15,694
	Grumman Corp.	32,467	15,199
Waste M	anagement Inc.	83,949	15,035
3M Co.		126,440	13,822
	nnifin Corp.	29,423	13,555
	Dynamics Corp.	51,894	13,475
FedEx Co	•	52,992	13,405
•	n Group Inc. hnologies plc	12,672	12,819
	Electric Co.	52,313 130,593	12,759 12,711
	outhern Corp.	51,818	12,249
Cintas Co	•	19,817	11,943
PACCAR		119,797	11,698
	obal Corp.	192,307	11,048
* Copart In		200,264	9,813
	Fechnologies Inc.	43,404	9,142
	Controls International plc	155,819	8,981
	entals Inc.	15,538	8,910
Paychex I		73,609	8,768
AMETEK Fastenal		52,821	8,710
WW Grai		130,858 10,128	8,476 8,393
	dwide Corp.	93,628	8,333
	nion Freight Line Inc.	20,471	8,298

arket alue• \$000)			Shares	Market Value• (\$000)
		De ale call Actematica la a	00.000	
,552		Rockwell Automation Inc.	26,286	8,161
,933		Verisk Analytics Inc. Class A	33,195	7,929
,033		Cummins Inc.	32,454	7,775
,965		Republic Services Inc. Class A	46,785	7,715
,822		Quanta Services Inc.	33,294	7,185
,799		Ingersoll Rand Inc.	92,732	7,172
,684		Equifax Inc.	28,190	6,971
,060		Xylem Inc.	55,249	6,318
,981		Fortive Corp.	80,505	5,928
,827		Delta Air Lines Inc.	147,076	5,917
,487		Broadridge Financial Solutions Inc.	26,991	5,553
,460		Westinghouse Air Brake Technologies Corp.	40,997	5,203
,457		Dover Corp.	32,063	4,932
,416	J	Howmet Aerospace Inc.	89,671	4,853
,294	*	Builders FirstSource Inc.	28,236	4,714
,008		Expeditors International of Washington Inc.	33,264	4,231
,542	*	Axon Enterprise Inc.	16,147	4,171
,474		Veralto Corp.	50,191	4,129
,085		Hubbell Inc. Class B	12,283	4,040
,981		Southwest Airlines Co.	136,572	3,944
,789		IDEX Corp.	17,337	3,764
,774		Jacobs Solutions Inc.	28,863	3,746
,689		JB Hunt Transport Services Inc.	18,620	3,719
,684		Textron Inc.	44,845	3,606
,273		Snap-on Inc.	12,073	3,487
,128		Stanley Black & Decker Inc.	35,127	3,446
,857		Masco Corp.	51,321	3,437
,736		Leidos Holdings Inc.	31,448	3,404
,556		Nordson Corp.	12,421	3,281
,287	*	United Airlines Holdings Inc.	74,875	3,089
		Rollins Inc.	64,457	2,815
,054		Pentair plc	37,831	2,751
		Allegion plc	20,150	2,553
,541	*	Ceridian HCM Holding Inc.	35,807	2,403
,291		Huntington Ingalls Industries Inc.	9,068	2,354
,948		Paycom Software Inc.	11,235	
,813				2,323
,658		A O Smith Corp.	28,123	2,318
,019		CH Robinson Worldwide Inc.	26,693	2,306
,706	*	Robert Half Inc.	24,201	2,128
,043	*	American Airlines Group Inc.	150,041	2,062
,526		Generac Holdings Inc.	14,050 _	1,816
,915				807,774
,018	Info	ormation Technology (28.7%)		
,941		Apple Inc.	3,348,120	644,614
,426		Microsoft Corp.	1,702,108	640,061
,694		NVIDIA Corp.	565,672	280,132
,199		Broadcom Inc.	100,525	112,211
,035	*	Adobe Inc.	104,272	62,209
,822	*	Salesforce Inc.	222,833	58,636
,555	*	Advanced Micro Devices Inc.	370,018	54,544
,475		Accenture plc Class A	143,730	50,436
,405		Intel Corp.	965,534	48,518
,819		Cisco Systems Inc.	927,540	46,859
,759		Intuit Inc.	64,183	40,116
,711		Oracle Corp.	363,876	38,363
,249		QUALCOMM Inc.	254,886	36,864
,243		Texas Instruments Inc.	207,974	35,451
,040 ,698		International Business Machines Corp.	207,374	34,200
,030 ,048	*	ServiceNow Inc.	46,948	
				33,168
,813 ,142		Applied Materials Inc.	191,573 30 182	31,048 23.640
		Lam Research Corp.	30,182	23,640
,981		Analog Devices Inc.	114,108 251,464	22,657
,910	*	Micron Technology Inc.	251,464	21,460
,768		Palo Alto Networks Inc.	71,184	20,991
,710	*	KLA Corp.	31,129	18,095
,476	*	Synopsys Inc.	34,829	17,934
,393	*	Cadence Design Systems Inc.	62,305	16,970
,377		Arista Networks Inc.	57,724	13,595
,298		Amphenol Corp. Class A	137,067	13,588

			Market
		Shares	Value* (\$000)
	NXP Semiconductors NV	59,026	13,557
	Roper Technologies Inc.	24,474	13,343
*	Autodesk Inc.	48,973	11,924
	Motorola Solutions Inc.	38,027	11,906
	Microchip Technology Inc.	123,967	11,179
	TE Connectivity Ltd. Cognizant Technology Solutions Corp. Class A	71,230 114,950	10,008 8,682
*	Fortinet Inc.	146,116	8,552
*	ON Semiconductor Corp.	98,742	8,248
*	Gartner Inc.	17,873	8,063
*	ANSYS Inc.	19,873	7,212
	CDW Corp.	30,653	6,968
*	Monolithic Power Systems Inc.	10,960	6,913
*	Fair Isaac Corp.	5,654	6,581
	Keysight Technologies Inc. HP Inc.	40,623 199,568	6,463 6,005
	Corning Inc.	176,104	5,362
	Hewlett Packard Enterprise Co.	293,504	4,984
*	Teledyne Technologies Inc.	10,826	4,832
*	PTC Inc.	27,205	4,760
*	First Solar Inc.	24,472	4,216
*	NetApp Inc.	47,768	4,211
*	VeriSign Inc.	20,319	4,185
	Enphase Energy Inc. Skyworks Solutions Inc.	31,260 36,518	4,131 4,105
*	Akamai Technologies Inc.	34,504	4,103
*	Tyler Technologies Inc.	9,653	4,036
*	EPAM Systems Inc.	13,199	3,925
*	Western Digital Corp.	74,182	3,885
	Seagate Technology Holdings plc	44,507	3,800
	Teradyne Inc.	34,965	3,794
*	Jabil Inc.	29,270	3,729
*	Zebra Technologies Corp. Class A Trimble Inc.	11,783 56,828	3,221 3,023
	Gen Digital Inc.	129,114	2,946
*	Qorvo Inc.	22,328	2,514
*	F5 Inc.	13,658	2,445
	Juniper Networks Inc.	72,938	2,150
N/1-	aterials (2.4%)	2	2,646,302
IVIC	Linde plc	111,038	45,604
	Sherwin-Williams Co.	53,932	16,821
	Freeport-McMoRan Inc.	328,312	13,976
	Air Products and Chemicals Inc.	50,869	13,928
	Ecolab Inc.	58,169	11,538
	Newmont Corp.	264,013	10,928
	Nucor Corp.	56,353	9,808
	Dow Inc.	160,804	8,819
	PPG Industries Inc. Corteva Inc.	53,965 161,223	8,070 7,726
	DuPont de Nemours Inc.	98,389	7,720
	Martin Marietta Materials Inc.	14,137	7,053
	Vulcan Materials Co.	30,468	6,917
	LyondellBasell Industries NV Class A	58,785	5,589
	International Flavors & Fragrances Inc.	58,498	4,737
	Ball Corp.	72,157	4,150
	Steel Dynamics Inc.	34,807	4,111
	Albemarle Corp.	26,842	3,878
	Avery Dennison Corp. Celanese Corp. Class A	18,424 22,945	3,725 3,565
	CF Industries Holdings Inc.	43,706	3,565 3,475
	Packaging Corp. of America	20,509	3,341
	Amcor plc	330,744	3,188
	International Paper Co.	79,470	2,873
	Mosaic Co.	74,769	2,672
	Eastman Chemical Co.	27,258	2,448

	Shares	Market Value (\$000)
Westrock Co.		
FMC Corp.	58,656 28,444	2,435 1,793
		220,737
Real Estate (2.5%)		220,707
Prologis Inc.	211,618	28,209
American Tower Corp.	106,768	23,049
Equinix Inc.	21,503	17,318
Crown Castle Inc.	99,432	11,454
Welltower Inc.	126,802	11,434
Public Storage	36,217	11,046
Simon Property Group Inc.	74,642	10,647
Realty Income Corp.	165,645	9,511
Digital Realty Trust Inc.	69,297	9,326
* CoStar Group Inc.	93,540	8,175
Extra Space Storage Inc.	48,430	7,765
VICI Properties Inc. Class A	236,732	7,547
* CBRE Group Inc. Class A	69,773	6,495
SBA Communications Corp. Class A	24,682	6,262
AvalonBay Communities Inc.	32,563	6,096
Weyerhaeuser Co.	167,199	5,814
Equity Residential	79,256	4,847
Iron Mountain Inc.	66,847	4,678
Ventas Inc.	92,161	4,593
Alexandria Real Estate Equities Inc.	35,830	4,542
Invitation Homes Inc.	131,691	4,492
Essex Property Trust Inc.	14,723	3,650
Mid-America Apartment Communities Inc.	26,766	3,599
Kimco Realty Corp.	152,293	3,245
Host Hotels & Resorts Inc.	161,409	3,143
UDR Inc.	69,142	2,648
Regency Centers Corp.	37,537	2,515
Healthpeak Properties Inc.	125,677	2,488
Camden Property Trust	24,514	2,434
Boston Properties Inc.	32,979	2,314
Federal Realty Investment Trust	16,800 _	1,731
Utilities (2.3%)		231,067
NextEra Energy Inc.	469,881	28,541
Southern Co.	249,740	17,512
Duke Energy Corp.	176,486	17,126
Sempra	144,215	10,777
American Electric Power Co. Inc.	120,312	9,772
Dominion Energy Inc.	191,607	9,006
PG&E Corp.	488,071	8,800
Constellation Energy Corp.	73,066	8,541
Exelon Corp.	227,783	8,177
Xcel Energy Inc.	126,499	7,832
Consolidated Edison Inc.	79,029	7,189
Public Service Enterprise Group Inc.	113,979	6,970
Edison International	87,839	6,280
WEC Energy Group Inc.	72,330	6,088
American Water Works Co. Inc.	44,520	5,876
DTE Energy Co.	47,272	5,212
Eversource Energy	80,013	4,938
Entergy Corp.	48,482	4,906
PPL Corp.	169,016	4,580
Ameren Corp.	60,231	4,357
FirstEnergy Corp.	118,112	4,330
CenterPoint Energy Inc.	144,732	4,135
Atmos Energy Corp.	34,005	3,941
CMS Energy Corp.	66,875	3,883
Alliant Energy Corp.	58,380	2,995
	153,567	2,956
AES Corp.		
AES Corp. Evergy Inc.	52,711	2,752
	52,711 51,648	2,752 2,670

	Shares	Market Value• (\$000)
Pinnacle West Capital Corp.	25,972	1,866
	-	214,523
Total Common Stocks (Cost \$4,687,204)		9,169,694
Temporary Cash Investments (0.4%)		
Money Market Fund (0.4%) ^{2,3} Vanguard Market Liquidity Fund, 5.435% (Cost \$36,116)	361,199	36,113
Total Investments (99.8%) (Cost \$4,723,320)	:	9,205,807
Other Assets and Liabilities-Net (0.2%)		16,566
Net Assets (100%)		9,222,373

Cost is in \$000.

• See Note A in Notes to Financial Statements.

* Non-income-producing security.

 Includes partial security positions on loan to broker-dealers. The total value of securities on loan is \$104,000.

2 Affiliated money market fund available only to Vanguard funds and certain trusts and accounts managed by Vanguard. Rate shown is the 7-day yield.

3 Collateral of \$112,000 was received for securities on loan.

Derivative Financial Instruments Outstanding as of Period End					
Futures Contracts	Futures Contracts				
				(\$000)	
	Expiration	Number of Long (Short) Contracts	Notional Amount	Value and Unrealized Appreciation (Depreciation)	
Long Futures Contracts					
E-mini S&P 500 Index	March 2024	223	53,743	994	

Statement of Assets and Liabilities As of December 31, 2023

(\$000s, except shares, footnotes, and per-share amounts)	Amount
Assets	
Investments in Securities, at Value ¹	
Unaffiliated Issuers (Cost \$4,687,204)	9,169,694
Affiliated Issuers (Cost \$36,116)	36,113
Total Investments in Securities	9,205,807
Investment in Vanguard	291
Cash Collateral Pledged—Futures Contracts	2,274
Receivables for Investment Securities Sold	48
Receivables for Accrued Income	8,684
Receivables for Capital Shares Issued	7,894
Variation Margin Receivable—Futures Contracts	330
Total Assets	9,225,328
Liabilities	
Due to Custodian	503
Payables for Investment Securities Purchased	361
Collateral for Securities on Loan	112
Payables for Capital Shares Redeemed	1,416
Payables to Vanguard	563
Total Liabilities	2,955
Net Assets	9,222,373

1 Includes \$104,000 of securities on loan.

At December 31, 2023, net assets consisted of:

Paid-in Capital	4,235,946
Total Distributable Earnings (Loss)	4,986,427
Net Assets	9,222,373
Net Assets	
Applicable to 151,467,667 outstanding \$.001 par value shares of beneficial interest (unlimited authorization)	9,222,373
Net Asset Value Per Share	\$60.89

Statement of Operations

	Year Ended December 31, 2023
	(\$000)
Investment Income	(\$000)
Income	
 Dividends ¹	137,726
Interest ²	1,383
Securities Lending—Net	5
Total Income	139,114
Expenses	
The Vanguard Group—Note B	
Investment Advisory Services	246
Management and Administrative	10,784
Marketing and Distribution	436
Custodian Fees	70
Auditing Fees	74
Shareholders' Reports	111
Trustees' Fees and Expenses	5
Other Expenses	21
Total Expenses	11,747
Net Investment Income	127,367
Realized Net Gain (Loss)	
Investment Securities Sold ²	377,884
Futures Contracts	2,760
Realized Net Gain (Loss)	380,644
Change in Unrealized Appreciation (Depreciation)	
Investment Securities ²	1,452,410
Futures Contracts	2,083
Change in Unrealized Appreciation (Depreciation)	1,454,493
Net Increase (Decrease) in Net Assets Resulting from Operations	1,962,504

1 Dividends are net of foreign withholding taxes of \$37,000.

2 Interest income, realized net gain (loss), capital gain distributions received, and change in unrealized appreciation (depreciation) from an affiliated company of the portfolio were \$1,291,000, (\$2,000), less than \$1,000, and (\$3,000), respectively. Purchases and sales are for temporary cash investment purposes.

Statement of Changes in Net Assets

	Year Ended December 31,	
	2023 (\$000)	2022 (\$000)
Increase (Decrease) in Net Assets		
Operations		
Net Investment Income	127,367	119,202
Realized Net Gain (Loss)	380,644	267,407
Change in Unrealized Appreciation (Depreciation)	1,454,493	(2,080,128)
Net Increase (Decrease) in Net Assets Resulting from Operations	1,962,504	(1,693,519)
Distributions		
Total Distributions	(385,336)	(465,299)
Capital Share Transactions		
Issued	670,469	849,472
Issued in Lieu of Cash Distributions	385,336	465,299
Redeemed	(1,002,164)	(918,334)
Net Increase (Decrease) from Capital Share Transactions	53,641	396,437
Total Increase (Decrease)	1,630,809	(1,762,381)
Net Assets		
Beginning of Period	7,591,564	9,353,945
End of Period	9,222,373	7,591,564

Financial Highlights

For a Share Outstanding			Year	Ended Dec	ember 31,
Throughout Each Period	2023	2022	2021	2020	2019
Net Asset Value, Beginning of Period	\$50.74	\$65.47	\$53.76	\$47.70	\$38.03
Investment Operations					
Net Investment Income ¹	.833	.806	.738	.798	.805
Net Realized and Unrealized Gain (Loss) on Investments	11.870	(12.244)	13.978	7.014	10.791
Total from Investment Operations	12.703	(11.438)	14.716	7.812	11.596
Distributions					
Dividends from Net Investment Income	(.794)	(.758)	(.754)	(.806)	(.834)
Distributions from Realized Capital Gains	(1.759)	(2.534)	(2.252)	(.946)	(1.092)
Total Distributions	(2.553)	(3.292)	(3.006)	(1.752)	(1.926)
Net Asset Value, End of Period	\$60.89	\$50.74	\$65.47	\$53.76	\$47.70
Total Return	26.11%	-18.23%	28.55%	18.20%	31.30%
Ratios/Supplemental Data					
Net Assets, End of Period (Millions)	\$9,222	\$7,592	\$9,354	\$7,555	\$6,458
Ratio of Total Expenses to Average Net Assets	0.14%	0.14% ²	0.14%	0.14%	0.14%
Ratio of Net Investment Income to Average Net Assets	1.52%	1.48%	1.25%	1.73%	1.87%
Portfolio Turnover Rate	5%	5%	4%	8%	4%

1 Calculated based on average shares outstanding.

2 The ratio of expenses to average net assets for the period net of reduction from custody fee offset arrangements was 0.14%.

Notes to Financial Statements

The Equity Index Portfolio, a portfolio of Vanguard Variable Insurance Funds, is registered under the Investment Company Act of 1940 as an open-end investment company. The portfolio's shares are only available for purchase by separate accounts of insurance companies as investments for variable annuity plans, variable life insurance contracts, or other variable benefit insurance contracts.

A. The following significant accounting policies conform to generally accepted accounting principles for U.S. investment companies. The portfolio consistently follows such policies in preparing its financial statements.

1. Security Valuation: Securities are valued as of the close of trading on the New York Stock Exchange (generally 4 p.m., Eastern time) on the valuation date. Equity securities are valued at the latest quoted sales prices or official closing prices taken from the primary market in which each security trades; such securities not traded on the valuation date are valued at the mean of the latest quoted bid and asked prices. Securities for which market quotations are not readily available, or whose values have been affected by events occurring before the portfolio's pricing time but after the close of the securities' primary markets, are valued by methods deemed by the valuation designee to represent fair value and subject to oversight by the board of trustees. Investments in Vanguard Market Liquidity Fund are valued at that fund's net asset value.

2. Futures Contracts: The portfolio uses index futures contracts to a limited extent, with the objectives of maintaining full exposure to the stock market, maintaining liquidity, and minimizing transaction costs. The portfolio may purchase futures contracts to immediately invest incoming cash in the market, or sell futures in response to cash outflows, thereby simulating a fully invested position in the underlying index while maintaining a cash balance for liquidity. The primary risks associated with the use of futures contracts are imperfect correlation between changes in market values of stocks held by the portfolio and the prices of futures contracts, and the possibility of an illiquid market. Counterparty risk involving futures is mitigated because a regulated clearinghouse is the counterparty instead of the clearing broker. To further mitigate counterparty risk, the portfolio trades futures contracts on an exchange, monitors the financial strength of its clearing brokers and clearinghouse, and has entered into clearing agreements with its clearing brokers. The clearinghouse imposes initial margin requirements to secure the portfolio's performance and requires daily settlement of variation margin representing changes in the market value of each contract. Any securities pledged as initial margin for open contracts are noted in the Schedule of Investments.

Futures contracts are valued at their quoted daily settlement prices. The notional amounts of the contracts are not recorded in the Statement of Assets and Liabilities. Fluctuations in the value of the contracts are recorded in the Statement of Assets and Liabilities as an asset (liability) and in the Statement of Operations as unrealized appreciation (depreciation) until the contracts are closed, when they are recorded as realized gains (losses) on futures contracts.

During the year ended December 31, 2023, the portfolio's average investments in long and short futures contracts represented less than 1% and 0% of net assets, respectively, based on the average of the notional amounts at each quarter-end during the period.

3. Federal Income Taxes: The portfolio intends to continue to qualify as a regulated investment company and distribute virtually all of its taxable income. The portfolio's tax returns are open to examination by the relevant tax authorities until expiration of the applicable statute of limitations, which is generally three years after the filing of the tax return. Management has analyzed the portfolio's tax positions taken for all open federal and state income tax years, and has concluded that no provision for income tax is required in the portfolio's financial statements.

4. Distributions: Distributions to shareholders are recorded on the ex-dividend date. Distributions are determined on a tax basis at the fiscal year-end and may differ from net investment income and realized capital gains for financial reporting purposes.

5. Securities Lending: To earn additional income, the portfolio lends its securities to qualified institutional borrowers. Security loans are subject to termination by the portfolio at any time, and are required to be secured at all times by collateral in an amount at least equal to the market value of securities loaned. Daily market fluctuations could cause the value of loaned securities to be more or less than the value of the collateral received. When this occurs, the collateral is adjusted and settled before the opening of the market on the next business day. The portfolio further mitigates its counterparty risk by entering into securities lending transactions only with a diverse group of prequalified counterparties, monitoring their financial strength, and entering into master securities lending agreements with its counterparties. The master securities lending agreements provide that, in the event of a counterparty's default (including bankruptcy), the portfolio may terminate any loans with that borrower, determine the net amount owed, and sell or retain the collateral up to the net amount owed to the portfolio; however, such actions may be subject to legal proceedings. While

collateral mitigates counterparty risk, in the event of a default, the portfolio may experience delays and costs in recovering the securities loaned. The portfolio invests cash collateral received in Vanguard Market Liquidity Fund, and records a liability in the Statement of Assets and Liabilities for the return of the collateral, during the period the securities are on loan. Collateral investments in Vanguard Market Liquidity Fund are subject to market appreciation or depreciation. Securities lending income represents fees charged to borrowers plus income earned on invested cash collateral, less expenses associated with the loan. During the term of the loan, the portfolio is entitled to all distributions made on or in respect of the loaned securities.

6. Credit Facilities and Interfund Lending Program: The portfolio and certain other funds managed by The Vanguard Group ("Vanguard") participate in a \$4.3 billion committed credit facility provided by a syndicate of lenders pursuant to a credit agreement and an uncommitted credit facility provided by Vanguard. Both facilities may be renewed annually. Each fund is individually liable for its borrowings, if any, under the credit facilities. Borrowings may be utilized for temporary or emergency purposes and are subject to the portfolio's regulatory and contractual borrowing restrictions. With respect to the committed credit facility, the participating funds are charged administrative fees and an annual commitment fee of 0.10% of the undrawn committed amount of the facility, which are allocated to the funds based on a method approved by the portfolio's Statement of Operations. Any borrowings under either facility bear interest at an agreed-upon spread plus the higher of the federal funds effective rate, the overnight bank funding rate, or the Daily Simple Secured Overnight Financing Rate inclusive of an additional agreed-upon spread. However, borrowings under the uncommitted credit facility may bear interest based upon an alternate rate agreed to by the portfolio and Vanguard.

In accordance with an exemptive order (the "Order") from the SEC, the portfolio may participate in a joint lending and borrowing program that allows registered open-end Vanguard funds to borrow money from and lend money to each other for temporary or emergency purposes (the "Interfund Lending Program"), subject to compliance with the terms and conditions of the Order, and to the extent permitted by the portfolio's investment objective and investment policies. Interfund loans and borrowings normally extend overnight but can have a maximum duration of seven days. Loans may be called on one business day's notice. The interest rate to be charged is governed by the conditions of the Order and internal procedures adopted by the board of trustees. The board of trustees is responsible for overseeing the Interfund Lending Program.

For the year ended December 31, 2023, the portfolio did not utilize the credit facilities or the Interfund Lending Program.

7. Other: Dividend income is recorded on the ex-dividend date. Non-cash dividends included in income, if any, are recorded at the fair value of the securities received. Interest income includes income distributions received from Vanguard Market Liquidity Fund and is accrued daily. Security transactions are accounted for on the date securities are bought or sold. Costs used to determine realized gains (losses) on the sale of investment securities are those of the specific securities sold.

B. In accordance with the terms of a Funds' Service Agreement (the "FSA") between Vanguard and the portfolio, Vanguard furnishes to the portfolio investment advisory, corporate management, administrative, marketing, and distribution services at Vanguard's cost of operations (as defined by the FSA). These costs of operations are allocated to the portfolio based on methods and guidelines approved by the board of trustees and are generally settled twice a month.

Upon the request of Vanguard, the portfolio may invest up to 0.40% of its net assets as capital in Vanguard. At December 31, 2023, the portfolio had contributed to Vanguard capital in the amount of \$291,000, representing less than 0.01% of the portfolio's net assets and 0.12% of Vanguard's capital received pursuant to the FSA. The portfolio's trustees and officers are also directors and employees, respectively, of Vanguard.

C. Various inputs may be used to determine the value of the portfolio's investments and derivatives. These inputs are summarized in three broad levels for financial statement purposes. The inputs or methodologies used to value securities are not necessarily an indication of the risk associated with investing in those securities.

Level 1—Quoted prices in active markets for identical securities.

Level 2—Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).

Level 3—Significant unobservable inputs (including the portfolio's own assumptions used to determine the fair value of investments). Any investments and derivatives valued with significant unobservable inputs are noted on the Schedule of Investments.

At December 31, 2023, 100% of the market value of the portfolio's investments and derivatives was determined based on Level 1 inputs.

D. Permanent differences between book-basis and tax-basis components of net assets, if any, are reclassified among capital accounts in the financial statements to reflect their tax character. These reclassifications have no effect on net assets or net asset value per share.

Temporary differences between book-basis and tax-basis components of total distributable earnings (loss) arise when certain items of income, gain, or loss are recognized in different periods for financial statement and tax purposes; these differences will reverse at some time in the future. The differences are primarily related to the deferral of losses from wash sales; and the recognition of unrealized gains or losses from certain derivative contracts. As of period end, the tax-basis components of total distributable earnings (loss) are detailed in the table as follows:

	Amount (\$000)
Undistributed Ordinary Income	125,996
Undistributed Long-Term Gains	378,281
Net Unrealized Gains (Losses)	4,482,150
Capital Loss Carryforwards	_
Qualified Late-Year Losses	_
Other Temporary Differences	_
Total	4,986,427

The tax character of distributions paid was as follows:

	Year Ended De	Year Ended December 31,	
	2023 Amount (\$000)	2022 Amount (\$000)	
Ordinary Income*	119,864	114,459	
Long-Term Capital Gains	265,472	350,840	
Total	385,336	465,299	

* Includes short-term capital gains, if any.

As of December 31, 2023, gross unrealized appreciation and depreciation for investments and derivatives based on cost for U.S. federal income tax purposes were as follows:

	Amount (\$000)
Tax Cost	4,723,657
Gross Unrealized Appreciation	4,888,329
Gross Unrealized Depreciation	(406,179)
Net Unrealized Appreciation (Depreciation)	4,482,150

E. During the year ended December 31, 2023, the portfolio purchased \$406,753,000 of investment securities and sold \$614,570,000 of investment securities, other than temporary cash investments.

The portfolio purchased securities from and sold securities to other Vanguard funds or accounts managed by Vanguard or its affiliates, in accordance with procedures adopted by the board of trustees in compliance with Rule 17a-7 of the Investment Company Act of 1940. For the year ended December 31, 2023, such purchases were \$31,908,000 and sales were \$26,128,000, resulting in net realized loss of \$9,379,000; these amounts, other than temporary cash investments, are included in the purchases and sales of investment securities noted above.

F. Capital shares issued and redeemed were:

	Year Ended December 31,	
	2023 Shares (000)	2022 Shares (000)
Issued	12,250	15,519
Issued in Lieu of Cash Distributions	7,687	7,787
Redeemed	(18,089)	(16,568)
Net Increase (Decrease) in Shares Outstanding	1,848	6,738

G. Significant market disruptions, such as those caused by pandemics (e.g., COVID-19 pandemic), natural or environmental disasters, war (e.g., Russia's invasion of Ukraine), acts of terrorism, or other events, can adversely affect local and global markets and normal market operations. Any such disruptions could have an adverse impact on the value of the portfolio's investments and portfolio performance.

To the extent the portfolio's investment portfolio reflects concentration in a particular market, industry, sector, country or asset class, the portfolio may be adversely affected by the performance of these concentrations and may be subject to increased price volatility and other risks.

The use of derivatives may expose the portfolio to various risks. Derivatives can be highly volatile, and any initial investment is generally small relative to the notional amount so that transactions may be leveraged in terms of market exposure. A relatively small market movement may have a potentially larger impact on derivatives than on standard securities. Leveraged derivatives positions can, therefore, increase volatility. Additional information regarding the portfolio's use of derivative(s) and the specific risks associated is described under significant accounting policies.

At December 31, 2023, one shareholder (an insurance company separate account whose holdings in the portfolio represent the indirect investment of Vanguard Variable Annuity contract holders) was the record or beneficial owner of 44% of the portfolio's net assets. If this shareholder were to redeem its investment in the portfolio, the redemption might result in an increase in the portfolio's expense ratio, cause the portfolio to incur higher transaction costs, or lead to the realization of taxable capital gains.

H. Management has determined that no events or transactions occurred subsequent to December 31, 2023, that would require recognition or disclosure in these financial statements.

Report of Independent Registered Public Accounting Firm

To the Board of Trustees of Vanguard Variable Insurance Funds and Shareholders of Equity Index Portfolio

Opinion on the Financial Statements

We have audited the accompanying statement of assets and liabilities, including the schedule of investments, of Equity Index Portfolio (one of the portfolios constituting Vanguard Variable Insurance Funds, referred to hereafter as the "Portfolio") as of December 31, 2023, the related statement of operations for the year ended December 31, 2023, the statement of changes in net assets for each of the two years in the period ended December 31, 2023, including the related notes, and the financial highlights for each of the five years in the period ended December 31, 2023 (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Portfolio as of December 31, 2023, the results of its operations for the year then ended, the changes in its net assets for each of the two years in the period ended December 31, 2023 and the financial highlights for each of the five years in the period ended December 31, 2023 in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Portfolio's management. Our responsibility is to express an opinion on the Portfolio's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Portfolio in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits of these financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our procedures included confirmation of securities owned as of December 31, 2023 by correspondence with the custodian, transfer agent and brokers; when replies were not received from brokers, we performed other auditing procedures. We believe that our audits provide a reasonable basis for our opinion.

/s/PricewaterhouseCoopers LLP Philadelphia, Pennsylvania February 15, 2024

We have served as the auditor of one or more investment companies in The Vanguard Group of Funds since 1975.

Tax information (unaudited)

For corporate shareholders, 95.9%, or if subsequently determined to be different, the maximum percentage allowable by law, of ordinary income (dividend income plus short-term gains, if any) for the fiscal year qualified for the dividends-received deduction.

The portfolio hereby designates \$481,000, or if subsequently determined to be different, the maximum amount allowable by law, of interest earned from obligations of the U.S. government which is generally exempt from state income tax.

The portfolio distributed \$265,472,000 as capital gain dividends (20% rate gain distributions) to shareholders during the fiscal year.

The S&P 500 Index is a product of S&P Dow Jones Indices LLC, a division of S&P Global, or its affiliates ("SPDJI"), and has been licensed for use by Vanguard. Standard & Poor's[®], and S&P[®] are registered trademarks of Standard & Poor's Financial Services LLC, a division of S&P Global ("S&P") and Dow Jones[®] is a registered trademark of Dow Jones Trademark Holdings LLC ("Dow Jones"). The trademarks have been licensed to SPDJI and have been sublicensed for use for certain purposes by Vanguard. Vanguard Equity Index Portfolio is not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, any of their respective affiliates (collectively, "S&P Dow Jones Indices"). S&P Dow Jones Indices make no representation or warranty, express or implied, to the owners of Vanguard Equity Index Portfolio or any member of the public regarding the advisability of investing in securities generally or in Vanguard Equity Index Portfolio particularly or the ability of the S&P 500 Index to track general market performance. S&P Dow Jones Indices' only relationship to Vanguard with respect to the S&P 500 Index is the licensing of the Index and certain trademarks, service marks and/or trade names of S&P Dow Jones Indices and/or its licensors. The S&P 500 Index is determined, composed and calculated by S&P Dow Jones Indices without regard to Vanguard or Vanguard Equity Index Portfolio. S&P Dow Jones Indices have no obligation to take the needs of Vanguard or the owners of Vanguard Equity Index Portfolio. S&P Dow Jones Indices are not responsible for and have not participated in the determination of the prices, and amount of Vanguard Equity Index Portfolio. The timing of the issuance or sale of Vanguard Equity Index Portfolio is to be converted into cash, surrendered or redeemed, as the case may be. S&P Dow Jones Indices have no obligation or liability in connection with the administration, marketing or trading of Vanguard Equity Index Portfolio. There is no assurance that investment products based on the S&P 500 Index will accurat

S&P DOW JONES INDICES DOES NOT GUARANTEE THE ADEQUACY, ACCURACY, TIMELINESS AND/OR THE COMPLETENESS OF THE S&P 500 INDEX OR ANY DATA RELATED THERETO OR ANY COMMUNICATION, INCLUDING BUT NOT LIMITED TO, ORAL OR WRITTEN COMMUNICATION (INCLUDING ELECTRONIC COMMUNICATIONS) WITH RESPECT THERETO. S&P DOW JONES INDICES SHALL NOT BE SUBJECT TO ANY DAMAGES OR LIABILITY FOR ANY ERRORS, OMISSIONS, OR DELAYS THEREIN. S&P DOW JONES INDICES MAKE NO EXPRESS OR IMPLIED WARRANTIES, AND EXPRESSLY DISCLAIMS ALL WARRANTIES, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE OR AS TO RESULTS TO BE OBTAINED BY VANGUARD, OWNERS OF VANGUARD EQUITY INDEX PORTFOLIO, OR ANY OTHER PERSON OR ENTITY FROM THE USE OF THE S&P 500 INDEX OR WITH RESPECT TO ANY DATA RELATED THERETO. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT WHATSOEVER SHALL S&P DOW JONES INDICES BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES INCLUDING BUT NOT LIMITED TO, LOSS OF PROFITS, TRADING LOSSES, LOST TIME OR GOODWILL, EVEN IF THEY HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, WHETHER IN CONTRACT, TORT, STRICT LIABILITY, OR OTHERWISE. THERE ARE NO THIRD PARTY BENEFICIARIES OF ANY AGREEMENTS OR ARRANGEMENTS BETWEEN S&P DOW JONES INDICES AND VANGUARD, OTHER THAN THE LICENSORS OF S&P DOW JONES INDICES.

The People Who Govern Your Fund

The trustees of your mutual fund are there to see that the fund is operated and managed in your best interests since, as a shareholder, you are a part owner of the fund. Your fund's trustees also serve on the board of directors of The Vanguard Group, Inc., which is owned by the Vanguard funds and provides services to them.

A majority of Vanguard's board members are independent, meaning that they have no affiliation with Vanguard or the funds they oversee, apart from the sizable personal investments they have made as private individuals. The independent board members have distinguished backgrounds in business, academia, and public service. Each of the trustees and executive officers oversees 208 Vanguard funds.

Information for each trustee and executive officer of the fund appears below. That information, as well as the Vanguard fund count, is as of the date on the cover of this fund report. The mailing address of the trustees and officers is PO. Box 876, Valley Forge, PA 19482. More information about the trustees is in the *Statement of Additional Information*, which can be obtained, without charge, by contacting Vanguard at 800-662-7447, or online at vanguard.com.

Interested Trustee¹

Mortimer J. Buckley

Born in 1969. Trustee since January 2018. Principal occupation(s) during the past five years and other experience: chairman of the board (2019-present) of Vanguard and of each of the investment companies served by Vanguard; chief executive officer (2018-present) of Vanguard; chief executive officer, president, and trustee (2018-present) of each of the investment companies served by Vanguard; president and director (2017-present) of Vanguard; and president (2018-present) of Vanguard Marketing Corporation. Chief investment officer (2013-2017), managing director (2002–2017), head of the Retail Investor Group (2006-2012), and chief information officer (2001-2006) of Vanguard. Member of the board of governors of the Investment Company Institute and the board of governors of FINRA.

Independent Trustees

Tara Bunch

Born in 1962. Trustee since November 2021. Principal occupation(s) during the past five years and other experience: head of global operations at Airbnb (2020–present). Vice president of AppleCare (2012–2020). Member of the board of directors of Out & Equal, the advisory board of the University of California, Berkeley School of Engineering, and the advisory board of Santa Clara University's Leavey School of Business.

Emerson U. Fullwood

Born in 1948. Trustee since January 2008. Principal occupation(s) during the past five years and other experience: executive chief staff and marketing officer for North America and corporate vice president (retired 2008) of Xerox Corporation (document management products and services). Former president of the Worldwide Channels Group, Latin America, and Worldwide Customer Service and executive chief staff officer of Developing Markets of Xerox. Executive in residence and 2009–2010 Distinguished Minett Professor at the Rochester Institute of Technology. Member of the board of directors of the University of Rochester Medical Center, the Monroe Community College Foundation, the United Way of Rochester, North Carolina A&T University, Roberts Wesleyan College, and the Rochester Philharmonic Orchestra. Trustee of the University of Rochester.

F. Joseph Loughrey

Born in 1949. Trustee since October 2009. Principal occupation(s) during the past five years and other experience: president and chief operating officer (retired 2009) and vice chairman of the board (2008–2009) of Cummins Inc. (industrial machinery). Director of the V Foundation. Member of the advisory council for the College of Arts and Letters at the University of Notre Dame. Chairman of the board of Saint Anselm College.

Mark Loughridge

Born in 1953. Trustee since March 2012. Principal occupation(s) during the past five years and other experience: senior vice president and chief financial officer (retired 2013) of IBM (information technology services). Fiduciary member of IBM's Retirement Plan Committee (2004–2013), senior vice president and general manager (2002–2004) of IBM Global Financing, vice president and controller (1998–2002) of IBM, and a variety of other prior management roles at IBM. Member of the Council on Chicago Booth.

Scott C. Malpass

Born in 1962. Trustee since March 2012. Principal occupation(s) during the past five years and other experience: co-founder and managing partner (2022–present) of Grafton Street Partners (investment advisory firm). Chief investment officer (retired 2020) and vice president (retired 2020) of the University of Notre Dame. Chair of the board of Catholic Investment Services, Inc. (investment advisors). Member of the board of superintendence of the Institute for the Works of Religion, the Notre Dame 403(b) Investment Committee, and the board of directors of Paxos Trust Company (finance).

Deanna Mulligan

Born in 1963. Trustee since January 2018. Principal occupation(s) during the past five years and other experience: chief executive officer of Purposeful (advisory firm for CEOs and C-level executives; 2021–present). Board chair (2020), chief executive officer (2011–2020), and president (2010–2019) of The Guardian Life Insurance Company of America. Chief operating officer (2010–2011) and executive vice president (2008–2010) of Individual Life and Disability of the Guardian Life Insurance Company of America. Director of DuPont. Member of the board of the Economic Club of New York. Trustee of the Partnership for New York City (business leadership), Chief Executives for Corporate Purpose, and the NewYork-Presbyterian Hospital.

André F. Perold

Born in 1952. Trustee since December 2004. Principal occupation(s) during the past five years and other experience: George Gund Professor of Finance and Banking, Emeritus at the Harvard Business School (retired 2011). Chief investment officer and partner of HighVista Strategies (private investment firm). Member of the board of RIT Capital Partners (investment firm).

Sarah Bloom Raskin

Born in 1961. Trustee since January 2018. Principal occupation(s) during the past five years and other experience: deputy secretary (2014–2017) of the United States Department of the Treasury. Governor (2010–2014) of the Federal Reserve Board. Commissioner (2007–2010) of financial regulation for the State of Maryland. Colin W. Brown Distinguished Professor of the Practice of Law, Duke Law School (2021–present); Rubenstein Fellow, Duke University (2017–2020); Distinguished Fellow of the Global Financial Markets Center, Duke Law School (2020–2022); and Senior Fellow, Duke Center on Risk (2020–present). Partner of Kaya Partners (climate policy advisory services). Member of the board of directors of Arcadia (energy solution technology).

Grant Reid

Born in 1959. Trustee since July 2023. Principal occupation(s) during the past five years and other experience: chief executive officer and president (2014–2022) and member of the board of directors (2015–2022) of Mars, Incorporated (multinational manufacturer). Member of the board of directors of Marriott International, Inc. Chair of Agribusiness Task Force, Sustainable Markets Initiative.

David Thomas

Born in 1956. Trustee since July 2021. Principal occupation(s) during the past five years and other experience: president of Morehouse College (2018–present). Professor of business administration, emeritus at Harvard University (2017–2018). Dean (2011–2016) and professor of management (2016–2017) at the Georgetown University McDonough School of Business. Director of DTE Energy Company. Trustee of Common Fund.

Peter F. Volanakis

Born in 1955. Trustee since July 2009. Principal occupation(s) during the past five years and other experience: president and chief operating officer (retired 2010) of Corning Incorporated (communications equipment) and director of Corning

Incorporated (2000–2010) and Dow Corning (2001–2010). Director (2012) of SPX Corporation (multi-industry manufacturing). Overseer of the Amos Tuck School of Business Administration, Dartmouth College (2001–2013). Member of the BMW Group Mobility Council.

Executive Officers

Jacqueline Angell

Born in 1974. Principal occupation(s) during the past five years and other experience: principal of Vanguard. Chief compliance officer (November 2022–present) of Vanguard and of each of the investment companies served by Vanguard. Chief compliance officer (2018–2022) and deputy chief compliance officer (2017–2019) of State Street.

Christine M. Buchanan

Born in 1970. Principal occupation(s) during the past five years and other experience: principal of Vanguard. Chief financial officer (2021–present) and treasurer (2017–2022) of each of the investment companies served by Vanguard. Partner (2005–2017) at KPMG (audit, tax, and advisory services).

John Galloway

Born in 1973. Principal occupation(s) during the past five years and other experience: principal of Vanguard. Investment stewardship officer (September 2020–present) of each of the investment companies served by Vanguard. Head of Investor Advocacy (February 2020–present) and head of Marketing Strategy and Planning (2017–2020) at Vanguard. Special assistant to the President of the United States (2015).

Ashley Grim

Born in 1984. Principal occupation(s) during the past five years and other experience: treasurer (February 2022–present) of each of the investment companies served by Vanguard. Fund transfer agent controller (2019–2022) and director of Audit Services (2017–2019) at Vanguard. Senior manager (2015–2017) at PriceWaterhouseCoopers (audit and assurance, consulting, and tax services).

Jodi Miller

Born in 1980. Principal occupation(s) during the past five years and other experience: principal of Vanguard. Finance director (2022–present) of each of the investment companies served by Vanguard. Head of Enterprise Investment Services (2020–present), head of Retail Client Services and Operations (2020–2022), and head of Retail Strategic Support (2018–2020) at Vanguard.

Anne E. Robinson

Born in 1970. Principal occupation(s) during the past five years and other experience: general counsel (2016–present) of Vanguard. Secretary (2016–present) of Vanguard and of each of the investment companies served by Vanguard. Managing director (2016–present) of Vanguard. Managing director and general counsel of Global Cards and Consumer Services (2014–2016) at Citigroup. Counsel (2003–2014) at American Express. Nonexecutive director (2022–present) of the board of National Grid (energy).

Michael Rollings

Born in 1963. Principal occupation(s) during the past five years and other experience: finance director (2017–present) and treasurer (2017) of each of the investment companies served by Vanguard. Managing director (2016–present) of Vanguard. Chief financial officer (2016–present) of Vanguard. Director (2016–present) of Vanguard Marketing Corporation. Executive vice president and chief financial officer (2006–2016) of MassMutual Financial Group.

Vanguard Senior Management Team

Matthew Benchener	Thomas M. Rampulla
Joseph Brennan	Karin A. Risi
Mortimer J. Buckley	Anne E. Robinson
Gregory Davis	Michael Rollings
John James	Nitin Tandon
Chris D. McIsaac	Lauren Valente

Vanguard

Connect with Vanguard[®] > vanguard.com

Fund Information > 800-662-7447

Annuity and Insurance Services > 800-522-5555

Institutional Investor Services > 800-523-1036 Text Telephone for People

Who Are Deaf or Hard of Hearing > 800-749-7273

This material may be used in conjunction with the offering of shares of any Vanguard fund only if preceded or accompanied by the fund's current prospectus.

All comparative mutual fund data are from Morningstar, Inc., unless otherwise noted.

You can obtain a free copy of Vanguard's proxy voting guidelines by visiting vanguard.com/proxyreporting or by calling Vanguard at 800-662-2739. The guidelines are also available from the SEC's website, www.sec.gov. In addition, you may obtain a free report on how your fund voted the proxies for securities it owned during the 12 months ended June 30. To get the report, visit either vanguard.com/proxyreporting or www.sec.gov.

You can review information about your portfolio on the SEC's website, and you can receive copies of this information, for a fee, by sending a request via email addressed to publicinfo@sec.gov.

Source for Bloomberg indexes: Bloomberg Index Services Limited. Copyright 2024, Bloomberg. All rights reserved.

© 2024 The Vanguard Group, Inc. All rights reserved. Vanguard Marketing Corporation, Distributor.

Q690TSMI 022024